 ________________________________ ________________________________ ________________________________ ________________________________ __________   
i  
 
 
 
Targeted AntiCoagulation Therapy to reduce Inflammation 
and Cellular Activation in Long-term HIV Disease 
(TACTICAL -HIV) 
  
ClinicalTrials.gov Identifier: # 
[STUDY_ID_REMOVED]  
 
Sponsored by:  
Minneapolis Medical Research Foundation  
 
Funding provided by:  
National Heart Lung and Blood Institute (NIH) : R01 HL126542  
 
Study drug provided by: Daiichi -Sankyo Pharmaceuticals  
 
Version Number: v2.0 
 
Day Month Year  
1-May-2016 
 
 
Protocol Chair:  Jason Baker , MD, MS  
 
Lead Statistician: Julian Wolfson, PhD  
 
Protocol Manager:  Namo Tetekpor , MPH, MS 
 
Protocol Team Members:  Nigel Key, Russell Tracy, Kathleen Brummel -Zeidens , Irini 
Sereti, Micah Mooberry , Jane Kennedy  
 
NOTE: This protocol was developed consistent with â€˜Standard Protocol Items: 
Recommendations for Intervention Trialsâ€™ (the SPIRIT initiative).1 
  

 ________________________________ ________________________________ ________________________________ ________________________________ __________   
ii Table of Contents  
1 INTRODUCTION  1 
1.1 BACKGROUND AND RATIONALE  1 
1.1.1  PREMISE  1 
1.1.2  SCIENTIFIC BACKGROUND  1 
1.2 HYPOTHESIS AND OBJECTIVES  4 
2 METHODOLOGY  4 
2.1 TRIAL DESIGN  4 
2.2 STUDY POPULATION  5 
2.2.1  INCLUSION CRITERIA  5 
2.2.2  EXCLUSION CRITERIA  5 
2.3 STUDY MEDICATION INT ERVENTION  6 
2.3.1  EDOXABAN  6 
2.3.2  RANDOMIZATION AND BLINDING  8 
2.3.3  STUDY DRUG PRODUCTION AND DISTRIBUTION  8 
2.4 OUTCOMES  8 
2.4.1  STUDY VISIT SCHEDULE  9 
2.4.2  POWER AND SAMPLE SIZE CONSIDERATIONS  10 
3 CLINICAL MANAGEMENT  11 
3.1 ADMINISTRATION OF STUDY PROCEDURES  11 
3.2 CATEGORIZATION OF BLEEDING EVENTS  12 
3.2.1  ISTH  DEFINITION OF MAJOR BLEEDING  12 
3.2.2  BLEEDING ACADEMIC RESEARCH CONSORTIUM (BARC)  DEFINITIONS  12 
3.3 STUDY MANAGEM ENT OF BLEEDING EVENTS  12 
3.4 STUDY DRUG CESSATION  13 
3.5 ADHERENCE AND TOLERABILITY  14 
3.6 CONCOMITANT MEDICATIONS AND ANTIRETROVIRAL THERAPY  14 
3.6.1  CONTRAINDICATED CONCO MITANT MEDIC ATIONS FOR THIS STUD Y INCLUDE : 14 
3.7 DATA COLLECTION  14 
3.8 BLOOD SPECIMEN PROCESSING  15 
3.9 CLINICAL LABS 15 
4 SAFETY AND ADVERSE E VENTS  15 
4.1 MEASURES TO REDUCE RI SK FOR ADVERSE EVENT S 15 
4.2 ADVERSE EVENT DEFINITIONS  15 
4.2.1  ADVERSE EVENT (AE):  15 
4.2.2  SERIOUS ADVERSE EVENT (SAE):  16 
4.2.3  UNANTICIPATED PROBLEM (UP):  16 
4.3 DOCUMENTING ADVERSE EVENTS AND UNANTICIPATED PROBLEMS  16 
4.3.1  ADVERSE EVENT RELATIONSHI P TO STUDY DRUG 17 
4.4 REPORTING SERIOUS ADVERSE EVENTS AND UNANTICIPATED PROBLEMS  17 
4.5 PARTICIPANT WITHDRAWAL  18 
 ________________________________ ________________________________ ________________________________ ________________________________ __________   
iii 5 DATA AND SAFETY MONI TORING PLAN  19 
5.1 INTERIM  ANALYSIS  19 
5.2 FREQUENCY AND CONTENT OF DATA AND SAFETY MONITORING  19 
5.2.1  SAFETY MONITORING BY DSMB  OFFICERS  19 
5.3 DSMB  (DATA AND SAFETY MONITORING BOARD ) 20 
5.3.1  DSMB  CONFLICT OF INTEREST AND PROTECTION OF CONFIDENTIALITY  20 
5.3.2  DSMB  RESPONSIBILITIES  21 
6 ANALYSIS PLAN  21 
APPENDIX A:  BLOOD S PECIMEN COLLECTION A ND STORAGE  1 
APPENDIX B:  BLEEDIN G ACADEMIC RESEARCH CONSO RTIUM (BARC) DEFINIT IONS  2 
APPENDIX C:  CLINICA L MANAGEMENT OF FACT OR X INHIBITOR BLEED ING EVENTS  3 
APPENDIX D:  DEFINIT ION AND CRITERIA FOR  AIDS EVENT  4 
APPENDIX E:  ADVERSE  EVENTS GRADING TABLE S (FROM NIH/DAIDS)  5 
APPENDIX F: ADVERSE EVENT REPORTING FORM  (FOR DSI)  35 
APPENDIX G: SAMPLE I NFORMED CONSENT FORM  (ICF)  1 
 
 
EDOXABAN INVESTIGATO R BROCHURE (PACKAGE INSERT) PROVIDED SEP ARATELY  
 
 
  
 ________________________________ ________________________________ ________________________________ ________________________________ __________   
iv List of Abbreviations  
AE Adverse Event/Adverse Experience  
AIDS  Acquired Immune Deficiency Syndrome  
ARB Angiotensin Receptor Blocker  
ART Antiretroviral Therapy  
BARC  Bleeding Academic Research Consortium  
BMP  Basic Metabolic Panel  
BP Blood Pressure  
CCC Clinical Coordinating Center  
CHD  Coronary Heart Disease  
CLIA  Clinical  Laboratory Improvement Amendments  
CONSORT  Consolidated Standards of Reporting Trials  
CRF Case Report Form  
CVD  Cardiovascular Disease  
DCC  Data and Coordinating  Center  
DM Diabetes Mellitus  
DSMB  Data and Safety Monitoring Board  
DVT Deep vein thrombosis  
ENGAGE AF -TIMI Effective anticoagulation with Factor Xa Next Generation in Atrial Fibrillation -
Thrombylysis in Myocardial Infarction 48  
ESPRIT  Evaluation of Subcutaneous ProleukinÂ® in a Randomized International Tria l 
F Factor (refering to a coagulation factor, designated by a Roman Numeral; e.g., 
FX) 
FDA Food and Drug Administration  
FXa Activated Factor X (ten)  
GCP  Good Clinical Practice  
GFR  Glomerular Filtration Rate  
HIPAA  Health Insurance Portability and Accountability Act  
HIV Human Immunodeficiency Virus  
ICF Informed Consent Form  
IL-6 Interleukin -6 
IND Investigational New Drug  
INSIGHT  International Network for Strategic Initiatives in Global HIV Trials  
IRB Institutional Review Board  
MP Microparticle  
N Number (typically refers to participants)  
NHLBI  National Heart Lung and Blood Institute , NIH  
NIAID  National Institute of Allergy and Infectious Diseases  
NIH National Institutes of Health  
OHRP  Office for Human Research Protections  
OHSR  Office for Human Subjects Research  
PAR Protease Activated Receptor  
PCA Procoagulant Activity  
PD Pharmacodynamics  
PBMC  Peripheral Blood Mononuclear Cells  
PHI Protected Health Information  
PI Principal Investigator  
PK Pharmacokinetics  
QA Quality Assurance  
QIA Quantitative Image Analysis  
QC Quality Control  
SAE Serious Adverse Event/Serious Adverse Experience  
SD Standard Deviation  
SILCAAT  Subcutaneous, Recombinant, Human Interleukin -2 in HIV -Infected Patients with 
Low CD4+ Counts Under Active Antiretroviral Therapy  
SMART  Strategic Management of AntiRetroviral Therapy  
TF Tissue Factor  
 ________________________________ ________________________________ ________________________________ ________________________________ __________   
v List of Abbreviations  
VTE Venous thromboembolism  
 
 
 
 Protocol Summary  
Full Title  Targeted Anticoagulation Therapy to Reduce Inflammation  and 
Cellular Activation in Long -term HIV Disease  
Short Title  TACT ICAL -HIV 
Clinical Trial Phase  Phase 2  
IND Sponsor  NA 
Conducted By  Minneapolis Medical Research Foundation and the University 
of Minnesota  
Principal 
Investigator  Jason Baker, MD, MS  
Lead Statistician  Julian Wolfson, PhD  
Sample Size  40 participants  
Study Population  HIV positive  patients  on stable ART with HIV RNA level  â‰¤200 
copies/mL , D-dimer level â‰¥100 mg/L (or ng/mL ), and no 
current/anticipated anti-platelet or anti -coagulation treatment  
Accrual Period  Anticipated enrollment 1 year  
Study Design  Cross -over placebo -controlled trial, where participants are 
randomize d 1:1 to the sequence they receive edoxaban  30mg 
or matched placebo daily (double -blind).  
Study Duration  12 months ; 4 months each of active drug, washout, and 
placebo  
Intervention  Edoxaban  30mg  versus matching placebo taken daily  
Primary Objective  To evaluate the effects of pharmacologic FXa inhibition (via 
edoxaban)  on inflammation, as reflected in plasma IL-6 levels  
Secondary 
Objectives  Evaluate  the effects of edoxaban  on monocyte and T-cell 
activation , coagulation and TF activity,  other blood markers of 
systemic inflammation, and adherence and tolerability  
  
 
 ________________________________ ________________________________ ________________________________ ________________________________ __________   
vi Schematic of Study Design : 
 
 
 
Statement of Compliance  
This trial will be conducted in compliance with the protocol, International Conference on 
Harmonization Good Clinical Practice E6 (ICH -GCP), and the applicable regulatory 
requirements including U.S. Code of Federal Regulations applicable to clinical studies (45 CFR 
46 and 21 CFR 50, 56 and 21 CFR 312), directive 2001 /20/EC on the approximation of the 
laws, regulations and administrative provisions of the Member States relating to the 
implementation of good clinical practice in the conduct of clinical trials on medicinal products for 
human use as amended by Commission Directive 2005/28/EC and NIAID Clinical Terms of 
Award.  All key personnel (all individuals responsible for the design and conduct of this study) 
have completed appropriate Human Subjects Protection Training.  
 

 Protocol Version 2.0  
 1 1 INTRODUCTION  
1.1 Background and Rationale  
1.1.1  Premise  
Understanding and mitigating persistent inflammation and coagulation activation is 
central to improving the quality and quantity of life for cont emporary HIV -positive 
persons. HIV treatment with antiretroviral therapy (ART) effectively and durably 
suppresses viral replication leading to improved survival and profound reductions in risk 
for AIDS, though excess clinical risk remains from non -AIDS -related end -organ 
diseases such as car diovascular disease (CVD). Findings from multiple epidemiologic 
studies have reported associations between inflammatory (e.g. interleukin -6 [IL-6]) and 
coagulation (e.g., D -dimer) biomarker levels  and risk for CVD and all -cause mortality, 
independent of traditional risk factors, HIV factors, and other biomarkers.  Furthermore, 
despite effective treatment with ART, IL -6 and D -dimer levels remain elevated when 
compared to uninfected persons, and pred ict both short - and long -term mortality over 8 
years of follow -up among treated HIV patients.  Currently, HIV -related alterations in 
coagulation biology that account for strong D -dimer clinical risk associations, including 
strategies to mitigate this risk,  remain poorly characterized.  
 
We propose a model where hypercoagulation contributes to disease risk , in part,  by 
amplifying inflammatory pathways, in addition to the direct effects of thrombogenesis.  
We hypothesize that increased generation of activated factor X (FXa) contributes to a 
systemic elevation in pro -inflammatory cytokine levels (e.g. interleukin -6 [IL-6]) among 
HIV positive patients.  This occurs, in part, via FXa activation of protease activated 
receptor 2 (PAR -2) on monocytes and tissue macro phages, which perpetuates innate 
inflammation. It is well established that inflammation up -regulates coagulation 
pathways, in part via tissue factor (TF) expression and alterations in key coagulation 
factors â€”we have shown that both mechanisms contribute to  HIV-related 
hypercoagulation. However, the notion that coagulation activity can itself amplify 
inflammatory pathways is a more recent, novel, and testable hypothesis for how low -
level hypercoagulation may contribute to excess disease risk among HIV patien ts. 
 
Expanding our understanding of these complex pathways is critical given somewhat 
inconsistent observations that: a) a number of hypercoagulable changes are present 
during chronic  HIV disease , while, b) clinically apparent clots do not account for most  of 
the long -term disease risk predicted by elevated D -dimer levels. The TACT ICAL -HIV 
trial is a critical step to advance this field, providing essential information on the 
underlying mechanisms and on candidate immunologic surrogate markers that will 
inform larger clinical trials of anticoagulant treatments for HIV positive patients.  
1.1.2  Scientific Background  
The Changing Spectrum of Morbidity and Mortality Among HIV Positive Patients:  
Antiretroviral therapy (ART)  effectively and durably suppresses HIV replica tion, leads to 
immune recovery (increasing CD4+ T -cell counts) and  prolonged life expectancy, and 
 Protocol Version 2.0  
 2 has changed the spectrum of morbidity and mortality among HIV positive persons.2-8 
Among well -treated patients with levels of HIV RNA below the l imit of detection, non -
AIDS -related conditions are now a more common cause of morbidity and mor tality than 
AIDS.6, 9-11 The most relevant serious non -AIDS -related diseases in current clinical 
practice include atherosclerotic cardiovascular disease (CVD), cancer, liver disease, 
end-stage renal disease, bone disease and subclinical neurocognitive dysfunction. Of 
these, CVD and cancer constitute the vast majority  of clinical events.5, 10-13 
 
Reasons for  Persistent Inflammation in Persons with ART -treated HIV Infection :  
Chronic inflammation in HIV disease arises from high levels of immune activation. HIV 
treatment with ART reduces activation of the immune response, including levels of 
inflammatory cytokines, though most immunologic abnorma lities persist compared to 
HIV uninfected persons.14, 15 HIV infection is classically associated with T -cell activation, 
reflecting adaptive immunity, but recent data demonstrate that innate immune  activation 
also contributes to chronic inflammation.16-20 The precise mechanisms driving high level 
immune activation are not entirely clear, but appear to involve both a persistent anti -HIV 
response (even with HIV RNA at low levels) and a more generalized immune activation 
(e.g., cytokine r elease).15, 21-23 Specifically, innocent bystande r activation â€”in which the 
pro-inflammatory aspects of HIV infection non -specifically drive T -cell and monocyte 
activation â€”also contributes.22, 24, 25 Othe r factors unique to HIV disease that may 
contribute to excess inflammation include: a) HIV -mediated destruction of gut 
epithelium, leading to greater translocation of bacterial products, b) dysregulated 
inflammatory responses to co -pathogens (e.g., CMV), a nd c) irreversible damage to the 
adaptive immune system (including lymphatic tissues).26-31  Treatments that reduce 
persistent inflammation among ART -treated HIV posit ive patients are lacking, and 
represents  an area of extensive research.32 
 
Potential P athologic Consequences of HIV-related Hypercoagulation : 
We have demonstrated that hypercoagulation in HIV disease arises, in part, from 
increases in tissue f actor (TF) procoagulant activity and alterations in the composition of 
coagulation factors.33, 34 Potential mechanisms driving these changes include:  a) non -
specific innate inflamm ation,35, 36 b) non -specific response to viral infections (e.g., 
interferon gamma release),37, 38 and c) HIV specific damage, e.g., loss of mucosal 
integrity with microbial translocation and TF activation.39 The net -result is 
hypercoagulation; this concept is supported by data from our group and others showing 
that D -dimer levels remain elevated in treated HIV disease.14, 39-41  
Although HIV is associated with increased risk for venous thromboembolic disease, very 
few clinical events predicted by D -dimer l evels include large vessel thrombosis.42 One 
explanation provided by non -human primate data suggests that hypercoagulation may 
manifest in end -organ damage via microvascular clotting resulting in thrombotic 
microangiopathy.43 This hypothesis is supported by the well -recognized association 
between HIV and thrombotic thrombocytopenic purpura (TTP).44 Another novel 
explanation entails our innovative aim 1 hypothesis, namely that hypercoagulation 
contributes to clinical r isk in treated HIV disease by up -regulating systemic 
inflammation, in part, via TF/VIIa and FXa activation of PAR -2 pathways ( Figure ).  
 Protocol Version 2.0  
 3 Recent data have established the 
interplay between coagulation and 
inflammation, including bi -
directional feedback .36 Protease 
activat ed receptors (PARs) play a 
central role in mediating this cross -
talk, as established in conditions 
like acute lung injury, sepsis and 
myocardial infarction.45, 46 PAR-1 is 
activated by various proteases, 
including FXa and thrombin, 
whereas PAR -2 is activated by the 
TF:FVIIa  complex, FXa, as well as 
other proteases47-50 In this 
proposal we use an experimental 
approach to test this hypothesis by blocking FXa  with low -dose edoxaban . 
 
Outcome s: IL-6 (and D -dimer)  Predict  Risk for  Non-AIDS  Defining Clinical Events :  
Excess risk for non -AIDS conditions is due to multiple factors, including a higher burden 
of traditional risk factors, but persistent inflammation despite ART is a key HIV-related 
risk factor . Recent data from a number of epidemiologic studies have shown t hat 
inflammatory biomarkers well validated in the aging and cardiovascular fields19, 51-54 are 
elevated with untreated and (to a lesser degree) treated HIV infection,14, 40, 55 and 
predict risk for CVD, cancer, and non -AIDS mortality.42, 56-61 Our group conducted a 
series of nested case -control and cohort studies  in collaboration with INSIGHT 
investigators , using data from 3 large HIV trials (SMART, ESPRIT, and SILCAAT), and 
determined that associations  for risk of  CVD, cancer, a composite of serious non -AIDS 
events, and all-cause mortal ity was most robust for levels of interleukin -6 (IL-6), as well 
as D-dimer ( Figure ).62-64 These associations are not attenuated by adjusting for HIV or 
traditional CVD risk factors,  are several -fold higher than reported in HIV -negative 
studies , and persist over a median of 5 .5 years of follow -up.  Importantly , these IL -6 and 
D-dimer asso ciations are independent of each other, making them  ideal candidate 
surrogate clinical risk 
marker s reflecting the 
potential harm from 
systemic inflammation 
and coagulation .42, 63, 65, 
66 An important 
implication is that any 
treatment candidate that 
down regulates both 
pathways (e.g., 
edoxaban) has 
significant potential for 
corresponding clinical 
benefit.  

 Protocol Version 2.0  
 4 1.2 Hypothesis and Objectives  
We hypothesize that increased generation of activated factor X (FXa) contributes to a 
systemic elevation in pro -inflammatory cytokine levels (e.g. IL -6) among HIV positive 
patients.  This occurs, in part, via FXa activation of protease activated receptor 2 (PAR -
2) on monocytes and tissue macrophages, which perpetuates innate inflammation .  We 
will test our hypothesis with an oral antagonist to FXa (edoxaban), and quantify the 
immunologic effects of PAR -2 inhibition on systemic i nflammation and monocyte 
activation.  We will  address the following specific objectives:  
 
ï‚· Primary Objective:  Evaluate the treatment effects of edoxaban  on systemic 
inflammation  
 
ï‚· Main  Secondary Objectives:   Evaluate the treatment effects of edoxaban on 
monocyte activation, tissue factor activity and coagulation.  
 
2 METHODOLOGY  
2.1 Trial Design  
The potential benefits of pharmacologic inhibition of FXa will be studied among HIV 
positive participants receiving ART with suppressed HIV viral load and a D -dimer > 100 
ng/mL.   The study design is  a cross -over placebo controlled randomized trial of 
edoxaban  30mg daily versus matched placebo (n=40  total participants ).  After screening 
and baseline visits, participants will be randomized to the sequence of drug 
adminis tration (i.e., edoxaban vs. placebo). The full visit sequence is listed below in 
Table 1.  After randomization, participants w ill start study medication #1 and follow -up 
for visits at months 1, 2, 3 and 4.  They w ill then stop study medication for 3 months , 
return for visits at months 7 and 8 (analogous to screening and baseline, respectively), 
then start study medication #2 and follow -up for visits at months 9, 10, 11, and 12.  
 
 
 
Table  1: Study Visit Timing and Measures  
Screening  
Baseline  
Month 1  
Month 2  
Month 3  
Month 4  
  Washout  
Month 7  
Month 8  
Month 9  
Month 10  
Month 11  
Month 12  
Study Medication #1 (e.g., edoxaban )  X X X X X        
Study Medication #2 (e.g., placebo)          X X X X X 
Blood measurements  X X X X X X  X X X X X X 
 
This cross -over design will efficiently study short -term treatment effects among a 
smaller sample. The half -life o f edoxaban is approximately 6-10 hours and treatment 
related changes in biomarkers such as IL -6 and D -dimer is typically present within 1 -2 
months . Thus, the washout period of 3 months extends beyond potential post -treatment 
effects, prior to starting study medication #2.  
The treatment effect (i.e., c hanges from pre-treatment  levels) over 4 months will be 
assessed in measures of inflammation, immune activation, tissue factor (TF) activity 
 Protocol Version 2.0  
 5 and coagulation .  For comparisons with placebo, e ach participant will then serve as his 
or her own control in this cross -over design.  
 
2.2 Study Population  
The target population  is HIV po sitive patients receiving effective ART treatment with 
viral suppression.  These participants are at low risk for AIDS progression, and low 
clinical event risk over the short term.  Health consequences in this population are 
largely due to non-AIDS definin g complications over the longer term, related to 
persistent inflammation and coagulation activity (e.g., CVD).  Participants must also not 
have co -morbid diseases known to be pro -inflammatory, or have current use of 
immune -modulatory or anti -coagulant drugs. Participants will be recruited from the 
HCMC HIV clinic, in Minneapolis, which provides care for 2000 HIV positive participants 
(>80% of whom are receiving ART with suppressed viral load).  
A D-dimer threshold of â‰¥100 ng/mL is used to improve the potenti al risk-benefit balan ce, 
by excluding those at the lowest clinical risk with little to no evi dence of coagulation 
activation.  This threshold corresponds approximately to the separation between the 1st 
(lowest) and 2nd quartile of D -dimer levels among ART -treated participants (n=3766) in 
our preliminary data ( see Figure of Kaplan Meier plots within scientific rationale above ).  
Participants with D -dimer levels in the 1st quartile had very low rates of clinical events 
during follow -up. This D -dimer threshold  enriches the target population with participants 
most likely to benefit while still studying the treatment effects over a wide range of 
coagulation activity.  Clinical lab measures of D -dimer will be used for screenin g only; 
outcome analyses will use D -dimer mea sures from the central  core lab. 
2.2.1  Inclusion Criteria  
ï‚· HIV infection (verified by previous positive antibody or detectable HIV RNA level)  
ï‚· Age â‰¥ 18 years  
ï‚· Receiving continuous  ART for â‰¥2  years  (regimen changes >3 months prior to 
enrollment are acceptable)  
ï‚· HIV RNA level  â‰¤200 copies/mL for â‰¥1 year  (1 measure â‰¥200 allowed if also < 500 
and preceded and followed by  one or more  values  â‰¤200 copies/mL ) 
ï‚· D-dimer level â‰¥100 ng/mL in FEU, or â‰¥50 ng/mL in DDU, measured within 60 days of 
randomization  
ï‚· Estimated creatinine clearance  â‰¥50 mL/min  
ï‚· Body weight â‰¥60kg  
ï‚· Do not anticipate starting (or stopping) statin or aspirin therapy during the study  
ï‚· For women of child bearing potential, agrees to use a reliable form of birth control  
2.2.2  Exclusion Criteria  
ï‚· Pregnancy  or breast feeding  
ï‚· A contra -indication to taking edoxaban  
ï‚· A clinical indication for anticoagulation therapy (e.g., atrial fibrillation or DVT/PE)  
 Protocol Version 2.0  
 6 ï‚· Treatment  with anti-platelet  or anti-coagulation  therapy ; prior treatment with aspirin 
is not itself an exclusion.  
ï‚· Daily NSAID use; periodic use (i.e., â‰¤3 days per week) is not itself an exclusion.  
ï‚· Treatment with systemic immune -modulatory therapy within the past 3 months.  
ï‚· Grade â‰¥1 hematology lab abnormality for INR (>1. 1 x ULN),  hemoglobin (<10.0 g/L ), 
platelets (<100 ,000 cells/ ï­L), or WBC ( <2,500 cells/mm3) 
ï‚· Grade â‰¥2 lab abnormality for chemistries ( i.e., BMP) or liver panel  
ï‚· No a lcohol  or illicit drug  abuse/dependency  currently, or anticipation of ongoing  use 
during study  
ï‚· History of prior myocardial infarction or unstable atherosclerotic disease  
ï‚· History of prior stroke or transient ischemic attack (TIA)  
ï‚· History of active gastrointestinal ulcer or bleeding disorder within the prior year  
ï‚· Intent to have surgery during the study period  (12 months)  
ï‚· Hepatitis C  treatments (e.g., interferon, ribavirin , protease inhibitors ) within the past 
3 months  
ï‚· Cirrhosis or hepatic impairment (e.g., Child -Pugh class B or C).  
ï‚· Seizure disorder  
ï‚· Previous /current  CNS space occupying lesion (e.g., Toxoplasmosis, mTB) with 
persistent abnormalities on CNS imaging  after completion of treatment.  
ï‚· Surgical or invasive procedure anticipated during study period.  
ï‚· Invasive cancer in the prior year or receiving cancer treatment ( not including 
carcinoma -in-situ or basal cell  cancer of the skin)  
ï‚· Rheumatologic or inflammatory disease, systemic in nature (e.g., systemic lupus 
erythemato sus, rheumatoid arthritis, vasculitis, sarcoid osis, Crohnâ€™s disease ) 
ï‚· Assessment by the clinical investigator that enrollment  into the study could entail 
excess risk to the participant, beyond what is intended or expected.  
 
2.3 Study Medication Intervention  
At baseline, p articipants will start blinded study medication, either edoxaban  or 
matching placebo at 3 0mg daily.  After 4 months they will stop study medication.  
Participants will remain off study drug between month 4 and month 8.  At the month 8 
visit, participants will again begin blinded study medication, corresponding to the 
comparison drug for that which was ta ken between baseline and month 4.  Thus, 
participants are randomized to either:  a) active study drug x4 months, washout (no 
drug), matched placebo x4 months, or b) matched placebo x4 months, washout (no 
drug), active study drug x4 months.  Double blinding  is maintained.  
Clinical labs, including HIV staging labs and coagulation measures, will be monitored  
prior to initiating each study medication and at 1 and 4 months after starting  each study 
medication (see Table 2  of study outcomes and visit schedule bel ow) 
2.3.1  Edoxaban  
Edoxaban is a competitive direct inhibitor of FXa , and will be used to test our central 
hypothesis that FXa activity (via PAR -2) contributes monocyte activa tion and systemic 
 Protocol Version 2.0  
 7 inflammation.   Edoxaban exhibits >10,000 -fold selectivity for FXa rel ative to thrombin, 
which exhibits immunologic cross -talk via activation of PAR -1.  Edoxaban is currently 
FDA-approved for stroke prevention in patients with non -valvular atrial fibrillation 
(NVAF) and as treatment for deep vein thrombosis (DVT) or pulmonary embolism (PE). 
The recommended dose is 60mg orally once daily for both indications (NVAF and 
DVT/PE).  The dose should be reduced to 30mg once daily for patients with  an 
estimated  creatinine clea rance of 30 -50 mL/min .  Finally, for the NVAF indication the 
FDA recommended not using edoxaban among patients with a creatinine clearance >95 
mL/min due to decreased efficacy in the prevention of ischemic stroke; given this was 
not due to an increase risk  for bleeding complications, there is no upper limit in 
creatinine clearance as part of the inclusion/exclusion criteria for TACTICAL -HIV. 
In the TACTICAL -HIV study, study drug will be taken as one 30mg dose of edoxaban 
(or matching placebo) daily in the m orning (AM) , and only participants with a creatinine 
clearance >50 mL/min will be enrolled.  
Pharmacokinetic properties of edoxaban include rapid absorption with attainment of 
peak plasma concentration within 1 -2 hours, and a half -life of approximately 6 -10 
hours.67  Metabolites are formed la rgely via hydrolysis with only minor contribution from 
cytochrome P450 (CYP) 3A.  There is little systemic accumulation of edoxaban at 10 
days after administration.67  Edoxaban can be administered with or without food, wi th 
little effect on bioavailability. Edoxaban is a substrate for the efflux transporter P -
glycoprotein (P -gp), and as a consequence serum levels may increase with concomitant 
admini stration of strong P -gp inhibit ors (e.g., verapamil, quinidine). Renal cleara nce 
likely involves active secretion .  
Risks associated with edoxaban use include bleeding.  Phase -3 clinical trial safety data 
arises from the ENGAGE AF -TIMI a nd Hokusai -VTE trials.68, 69 Major bleeding event, 
defined by the International Society on Thrombosis and Haemostasis, was 1.6% with 
edoxaban 30mg daily among those with atrial fibrillation in ENGAGE AF -TIMI, and also 
1.6% among those receiving a higher dose of edoxaban at  60mg for clinical VTE.68-70 In 
addition, in Hokusai -VTE study populations the rate of any clinically relevant bleeding 
was 8.5% for edoxaban (c ompared to 10.3% for warfarin).   The most common side 
effects overall in these studie s were bleeding, rash, abnormal liver tests, and anemia.  
The greatest potential for drug interactions entails the potential need for dose reduction 
with concomitant use of  P-gp inhibitors.  Concomitant administration of platelet -
inhibitors or NSAIDs may also increase bleeding risk.   Edoxaban is not safe for use 
during pregnancy.  
Routine clinical lab monitoring of coagulation tests are not indicated during edoxaban 
use.  Anti -factor Xa assay increases proportionally to serum levels of edoxaban.  
INR/PT and aPTT increase with edoxaban use, but to a highly variable degree.  
Episodes of bleeding from direct FXa inhibitors such as edoxaban are managed 
clinically with supportive care and potential use of Prothrombin Concentrate Complex 
(PCC).  
 Protocol Version 2.0  
 8 2.3.2  Randomization and Blinding  
Eligible participants who consent to study procedures will be random ized 1:1 to the 
sequence that they receive edoxaban  or matching placebo. Treatment assignments will 
be generated using a permuted block randomization scheme. Sites will use a secure, 
on-line program to obtain trea tment assignments.  The program  will also v erify eligibility 
and the existence of key baseline data. Treatment assignments will be verified and 
recorded in a dataset blinded to view by site staff.   
A bottle ID number (BID) unique to each bottle will be assigned to participants, and 
used by study st aff to obtain the correct blinded study drug  (active or placebo). Site staff  
will not have access to the treatment assignment linked to each bottle number, and 
bottle numbers will not be assigned in sequence.  
Blinding will occur at 3 levels:  1) treatment assignment will be blinded, 2) interim data 
summaries will blinded to all but the unblinded statistician and 3) core lab oratory  staff 
will be blinded to treatment group. In the rare event that the blind must be broken, every 
effort will be made to minimize  the extent of the unblinding (for staff and participants) 
and an assessment of blinding will occur at the end of the study . 
The blind may be broken in cases of a clinical bleeding event, where reversal of anti -
coagulation is being considered â€”e.g., with p rothrombin concentrate complex (PCC) .  
Procedures will be established for the study coordinator to obtain the key/blind for a 
given participant from the dispensing pharmacy.  
2.3.3  Study Drug Production and Distribution   
Active edoxaban 3 0mg tablets and matching placebo will be provided  and distributed  by 
Daiichi Sankyo, Inc .  Study drug will be provided in prepackaged bottles that include a 
one-month supply  plus additional drug to facilitate a visit window of +/- 2 weeks  (n=42 ).  
Each bottle will have a unique bo ttle ID number, along with appropriate packaging, 
license and content information per regulations.  Clinical site pharmacy will receive and 
store study drug until dispensing to participants or site staff (who then dispense to 
participants) in the context o f study visits. One bottle will be dispensed at baseline, and 
one additional bottle at the 1 , 2, and 3 -month study visits.  No study drug will be 
dispensed or taken between month 4 and 8, but one bottle will again be dispensed at 
the 8, 9, 10 and 11 -month study visit.  
  
The clinical site will communicate directly with the Daiichi Sankyo study team 
representative to ship  drug to sites.  Daiichi -Sankyo  will provide the DCC with the key 
linking the BID (unique to each bottle) with whether the contents are active edoxaban or 
matching placebo.  The DCC will then instruct sites which bottle(s) to dispense to 
patients based on the BID. 
2.4 Outcomes  
Primary Outcome  
ï‚· IL-6 plasma levels:  the difference between treatment and control conditions in 
change  from pre-treatment to on -treatment values   
 Protocol Version 2.0  
 9  
Secondary Outcomes  
ï‚· Adherence  
ï‚· Tolerability and side e ffects  
ï‚· Bleeding episodes:  Major bleeding and those defined as BARC Type 2, 3, 4, 5  
ï‚· Monocyte a ctivation:  cellular phenotypes (e.g., CD14+/ CD16+) , monocyte 
microparticles (MMPs),  and plasma biomarkers (e.g., sCD14, sCD163, TNF -Î±, 
sTNFr -1) 
ï‚· Functional TF pro -coagulant activity:  TF -positive microparticle (MPTF), cell -
associated TF, and whole blood TF  pro-coagulant activity  
ï‚· Coagulation activity (e.g., D -dimer levels , thrombin -antithrombin complex [TAT] , and 
functional thrombin potential assay ) 
ï‚· Endothelial activation:  endothelial cell microparticles (EMPs)  
ï‚· T-cell activation and senescence  phenotypes  in blood  
ï‚· Explore the potential impact of edoxaban co -administered with ART on viral 
suppression and the anti -inflammatory treatment effect (via subgroup analyses 
defined by type/class of antiretroviral use)  
 
Important Exploratory Analyses  
ï‚· Determine if the  treatment effect from Edoxapan differs depending on pre -treatment 
FXa activity (estimated from computational modeling)  
ï‚· Estimate the potential effect of Edoxaban treatment on clinical event risk (e.g., 
serious non -AIDS events , CVD, mortality, etc. ), as pre dicted by IL -6 and D -dimer 
associations with clinical risk.  
2.4.1  Study Visit Schedule  
Participants will be screened and, i f eligibility criteria are met, will be randomized at the 
baseline visit  to start active study drug or matched placebo (blinded).  Randomization 
will occur within 60 days  of screening .  
After screening  and baseline visit s, participants will start edoxaban 30mg once every 
morning (or matched placebo) .  They will return for study visits at months 1, 2, 3 and 4, 
after which they will stop study medication.  At month 7 and 8 they will return for repeat 
laboratory and study visit procedures.  After the month 8 study visit is completed, 
participants will r esume blinded study medication (either edoxaban 30mg or placebo, 
whichever was not given from baseline to month 4), and then follow -up for study visit 
procedures at months 9, 10, 11 and 12.  The visit schedule i s outlined in the table 
below. Patients will be fasting for all blood draws (except screening).  
 
Toxicity labs and a clinical assessment  will be ascertained as part of  follow -up study 
visits.  If clinical labs (e.g., HIV RNA level, CD4 count, BMP, hepatic panel, and CBC) 
are available as part of rout ine clinical monitoring during the study visit window, these 
results may be used in place of repeating clinic labs at the study visit.  If new symptoms 
develop that may be related to study medications, the site study investigator  is to be 
 Protocol Version 2.0  
 10 notified within 24  hours and a clinical determination is to be made whether additional 
toxicity labs and/or  adherence requires assessing . 
 
 
 
TABLE 2: Visit Timeline  
 
Screening  
Baseline  
Month 1  
Month 2  
Month 3  
Month 4  
Month 7  
Month 8  
Month 9  
Month 10  
Month 11  
Month 12  
ON STUDY DRUG AT VISIT  -- -- + + + + -- -- + + + + 
Informed consent and eligibility 
criteria  X -- -- -- -- -- -- -- -- -- -- -- 
Randomization  -- X -- -- -- -- -- -- -- -- -- --  
Clinical Assessments              
  Adherence  -- -- X X X X X X X X X X 
  Side Effect  Screen/Assessment  -- X X X X X X X X X X X 
  Bleeding & Adverse Events  -- X X X X X X X X X X X 
  Concomitant Medications  -- X X X X X X X X X X X 
Clinical Laboratory  Measures              
D-dimer screen  X* -- -- -- -- -- -- -- -- -- -- -- 
HIV viral load  X* X X X X X -- X X X X X 
CD4 count  -- X -- -- -- X -- X -- -- -- X 
CBC, INR, aPTT   X* X X X X X -- X X X X X 
Anti-Xa  X    X  X    X 
BMP, LFTs  X* X X -- -- X -- X X -- -- X 
Hep B s Ag & Hep C Ab  -- X* -- -- -- -- -- X* -- -- -- -- 
Lipid Panel  -- X -- -- -- -- -- -- -- -- -- -- 
Pregnancy test  (for women)  X -- X X X X -- X X X X X 
Study Outcomes              
Stored plasma  X X X X X X X X X X X X 
Stored PBMCs  -- X X -- -- X -- X X -- -- X 
*Lab values from anytime within 30 days of visit can be used ; previously positive hepatitis labs (i.e., HBsAg or 
HCV Ab) do not need to be repeated.  
 
2.4.2  Power and Sample Size Considerations  
The study employs a cross -over design, with participants serving as their own 
comparison.  To reduce variability in the primary outcome (log IL -6), we will average the 
2 pre -treatment measures ( i.e., screening and baseline  or months 7 and 8 ) as well as 
the 4 follow -up measures ( i.e., months 1, 2, 3, and 4 , or months 9, 10,  11, and 12 ). 
2.4.2.1  Primary outcome (IL -6) power and sample size  
We estimate that this cross -over design with n=40 participants will have 80% power at 
level alpha=0.05 to detect a treatment effect of 0.35 SD on log IL -6, corresponding to a 
23% relative differenc e in (non -log transformed) IL -6 levels between treatment 
conditions. In addition to the study and analysis structure described above, our 
simulation -based power calculation assumes a study attrition rate of 10% (i.e., 90% of 
subjects provide valid follow -up data). Measurements were simulated from the following 
random effects model:  ð‘Œð‘–ð‘—ð‘˜= ð›½0+ð‘0ð‘–+ ð›½1ð‘¡ð‘Ÿð‘¡ð‘–ð‘—âˆ—ð‘“ð‘¢ð‘–ð‘—+ ðœ–ð‘–ð‘—ð‘˜   , where ð‘¡ð‘Ÿð‘¡ð‘–ð‘— is the 
treatment indicator and ð‘“ð‘¢ð‘–ð‘— is the indicator that the measurement is a follow -up 
 Protocol Version 2.0  
 11 measureme nt. ð‘0ð‘– is an individual -specific random effect, and ðœ–ð‘–ð‘—ð‘˜ is the residual, 
assumed independent of ð‘0ð‘–.  ð‘0ð‘– and ðœ–ð‘–ð‘—ð‘˜ are assumed to be normally distributed with 
zero mean and variances chosen to simultaneously satisfy ð‘‰ð‘Žð‘Ÿ (ð‘Œð‘–ð‘—ð‘˜)= ð‘‰ð‘Žð‘Ÿ (ð‘0ð‘–)+
 ð‘‰ð‘Žð‘Ÿ (ðœ–ð‘–ð‘—ð‘˜)=0.55, and ðœŒ(ð‘Œð‘–ð‘—ð‘˜,ð‘Œð‘–ð‘—ð‘™)=ð‘‰ð‘Žð‘Ÿ (ð‘0ð‘–)
ð‘‰ð‘Žð‘Ÿ (ð‘0ð‘–)+ð‘‰ð‘Žð‘Ÿ (ðœ–ð‘–ð‘—ð‘˜) = 0.4, respectively the cross -
sectional variance and longitudinal correlation of log IL -6 observ ed in data from the 
SMART study . 
2.4.2.2  Power for secondary objectives  and exploratory analyses  
Few pilot data are available to characterize the correlation between multiple 
measurements of monocyte activation and monocyte TF -activity.  However, preliminary 
data provide  variance estimates for some of these markers.71 We conducted a 
simulat ion similar to that described for the primary outcome above , varying the 
between -time correlation of markers from 0.1 (low) to 0.7 (high). Across all cases, the 
given sample size gave at least 80% power to detect a 0.35 SD effect size, which 
corresponds to 22%, 32%, 24%, and 10% relative reductions in CD14+/CD16+, TF+, 
sCD163, and sCD14, re spectively.  For D -dimer, our study will have approximately 80% 
power to detect a 26% difference in (non -log transformed) levels of this marker between 
treatment conditions. Though data are unavailable on TAT, it is anticipated that the 
between -measurement correlation is likely to be the same and hence a 0.35 SD effect 
will correspond to a difference of approximately 20 -30% on this marker.  
Our analysis is also well -powered to detect a difference in treatment effect by degree of 
continuous pre -treatment FXa a ctivity: we estimate >80% power to detect a 0.25 SD log 
IL-6 difference in treatment effect (~22% relative difference on original IL -6 scale) 
between groups differing by 1 SD in FXa activity . 
The effects on IL -6 and D -dimer that we are well -powered to dete ct with our given 
sample size (i.e., ~25% reductions) correspond to estimated reductions of ~37% in the 
risk for the composite outcome of serious non -AIDS event (CVD, cancer, liver or renal 
event) or death (see Scientific Background 1.1.2 ), when using a jo int model and 
assuming both biomarkers are reduced by the same amount.  If one marker changes 
more than the other, e.g., a 30% reduction in D -dimer levels with a minimal 5 -10% 
reduction in IL -6 levels, this would correspond to a predicted 20% reduction in event risk 
(again, see IL-6 and D -dimer data in Scientific Background 1.1.2 ). 
 
3 CLINICAL MANAGEMENT  
3.1 Administration of Study Procedures  
Study  site coordinators  will be trained prior to study implementation and will perform all 
study visit procedures  during the conduct of the study .  The lead physician investigator 
will conduct clinical and drug toxicity assessments as indicated during the study.   
 Protocol Version 2.0  
 12 3.2 Categorization  of Bleeding Events  
All bleeding events will be categorized using the Bleeding Academic Research 
Consortium (BARC) definitions outlined below and in appendix B .  In addition a â€˜major 
bleedingâ€™ event will be de fined based on definitions established by the International 
Society  on Thrombosis and Haemostasis (ISTH).  
3.2.1  ISTH Definition of Major Bleeding  
Major bleeding in non -surgical patients are defined by the following criteria:  
ï‚· Fatal bleeding, and/or  
ï‚· Symptomatic bleeding in a critical area or organ, such as intracranial, 
intraspi nal, intraocular, retroperitoneal, intra -articular or pericardial, or 
intramuscular with compartment syndrome, and/or  
ï‚· Bleeding causing a fall  in hemoglobin level of â‰¥2 g/dL , or leading to transfusion 
of â‰¥2 units of whole blood or red cells.  
3.2.2  Bleeding Academic Research Consortium (BARC) Definitions  
BARC definitions are reviewed in detail in Appendix B, but briefly entail:  
ï‚· Type 0  â€“ No bleeding  
ï‚· Type 1  â€“ Bleeding  that is not actionable or requiring healthcare evaluation  
ï‚· Type 2  â€“ Overt bleeding beyond what would be expected for a clinical 
circumstance that requires healthcare evaluation but does not meet criteria for 
type 3, 4, or 5.  
ï‚· Type 3 â€“ Overt bleeding with hemoglobin drop >3 g/dL, bleeding requiring 
transfusion, intracranial hemorrhage, or bleeding int o other designated body 
compartments (e.g., cardiac tamponade)  
ï‚· Type 4 â€“ Bleeding related to cardiac surgery  
ï‚· Type 5 â€“ Fatal bleeding  
 
3.3 Study Management  of Bleeding E vents  
The site investigator will review all bleeding events, of any grade or severity, as soo n as 
the study team becomes aware of the event.  At that time, the event will be categorized 
in terms of BARC or ISTH classification and a corresponding decision will be made with 
respect to continuation of study drug.  
 
Participants with BARC Type 1 and 2 adverse bleeding episodes will continue with the 
study drug, unless assessment by the study investigator or medical care provider 
indicates that continuing on study  drug would be associated with escalation of the 
bleeding event or other excess risk in the clinical context.  
 
Participants with BARC Type 3 or a â€˜major b leedingâ€™ event will have the study 
medication permanently discontinued.  Participants must be followed regularly (e.g., 
weekly) until resolution of the adverse event.  
 
 Protocol Version 2.0  
 13 Any participant  planning to undergo a surgical procedure during the follow -up period 
should not be enrolled into the study.  If there is a need for a surgical procedure during 
the follow -up period, the study drug should be discontinued permanently.  It is important 
that the treating physician be made aware the participant may have been taking 
edoxaban (and oral FXa inhibitor).  
 
If any participant suffers a fatal bleed the blind for that participant will be broken.  If the 
participant were taking edoxaban at the time of th e event, the study will be temporarily 
stopped while the DSMB can review the event in the context of other clinical and safety 
information.  
 
Participants should be referred for acute medical evaluation with any overt clinical 
bleeding, bleeding consistent with BARC Type 2 or above,  or a major bleeding event.   
Study team investigators should immediately make the clinical treatment team aware 
that the study participant is potentially taking edoxaban, a factor Xa inhibitor; this should 
include a direct phone c all as well as documentation in the electronic health record.  
Clinical management will include standard of care along with cessation of study 
medication.   See APPENDIX C  for an approach to bleeding complications related to 
Factor Xa -inhibition with edoxab an.  NOTE:   Prothrombin concentrate complex (PCC ), 
such as K -Centra (i.e., replacement of factors II, VII, IX, and X),  may be effective in 
management of bleeding in the context of FXa inhibition, but there is no current antidote 
and dialysis is not effecti ve. 
 
3.4 Study Drug Cessation  
At baseline, participants will start blinded study medication consisting of edoxaban or 
matching placebo at 30mg every morning. No dose adjustment can be made during 
the study.  Tolerability, side effects, adverse events and clinical laboratory monitoring 
will be assessed at each study visit (via participant report and clinical labs), and at 
anytime during the study per the discretion of the clinical site investigator.   
 
If an ad verse event of grade â‰¥3 is assessed as related to study drug, study  medication 
should be stopped. If a grade 2 rash is persistent, study medication may also be 
stopped at the discretion of the site investigator.  Medication may also be stopped for 
grade <3  adverse events if the study investigator determines that the participant may be 
at risk for an escalation of the adverse event, persistent toxicity, or at risk in excess of 
what would be expected due to o ther contextual circumstances. If study medication was 
discontinued due to an adverse event of grade <3 that is not expected to recur, the 
study investigator may recommend re -initiating study medication.  
 
Any of the following will also result in stopping study medication  (see section 3.1.2) : 
i. Major bleeding  event  
ii. BARC Type 3 bleeding event   
iii. Any surgical procedure  with bleeding risk  
iv. Investigator or participant wishes to stop study medication  
 
 Protocol Version 2.0  
 14 3.5 Adherence and Tolerability  
Adherence will be assessed via participant self -report and pill count (by study 
coordinator s) during each follow -up visit.  Tolerability will also be assessed via self -
report, with additional laboratory assessments performed for toxicity.  
 
3.6 Concomitant Medications and Antiretroviral Therapy  
Any antiretroviral medication and ART regimen may be used that is recommended as a 
potential option in the US DHHS guidelines on use of ART for adults with HIV 
infection.72  
 
Concomitant medications will be assessed at every study visit.  Medications 
contraindica ted for this study include those that may increase risk of bleeding and/or 
substantially increase the effective exposure or serum drug levels of edoxaban (e.g., 
substrates for P -gp). NOTE:   There are numerous medications that are substrates for P -
glycoprot ein (P -gp), and therefore have potential to influence edoxa ban levels (and 
vice-a-versa). Concomitant medications associated with potential drug -drug interactions 
that are anticipated to be modest/minimal will not necessarily be contra -indicated for this 
short-term study  (e.g., atorvastatin, digoxin) . 
3.6.1  Contraindicated concomitant medications for this study include : 
i. Aspirin (daily use  >3 days ) 
ii. Platelet inhibitor (e.g., clopidogrel)  
iii. NSAIDs (daily use  >3 days ) 
iv. Fibrinolytic therapy  (within 1 month ) 
v. Verapamil  
vi. Quinidine  
vii. Amiodarone  
viii. Dronedarone  
ix. Ketaconazole and other azoles  
x. Erythromycin and other macrolides  
xi. Illicit drug use (e.g., cocaine)  
xii. Medications or drugs that may  be associated with unacceptable  increase 
risk to participants,  as determined by the study inves tigator.  
 
3.7 Data Collection  
All data will be entered into web -based case report forms and transferred to servers at 
the data coordinating center (DCC) at University of Minnesota School of Public Health 
using REDCap software.  Paper source documentation will also be kept in a secure, 
locked location at each clinical site.  Study coordinators  and/or other qualified research 
technicians will perform all blood draws and blood specimen processing.  
  
 Protocol Version 2.0  
 15 3.8 Blood Specimen Processing  
The blood specimen collection tubes and processing protocols are  outlined in the study 
laboratory manual.   Participants will be fasting for all study visit blood draws (optional for 
screening visit).  Plasma and serum specimens will need to be processed  from whole 
blood  within 1 hour  of collection.  Peripheral blood mon onuclear cell ( PBMC ) specimens 
will be processed locally at the University of Minnesota  and stored until analyzed by 
core immunology laboratory at the end of follow -up. 
3.9 Clinical Labs  
All clinical labs will be measured on fresh blood specimens the day of the study visit, at 
the HCMC clinical lab using CLIA approved standards .  D-dimer levels at screening will 
be assessed at HCMC using HemosIL D -Dimer HS, a latex -enhanced turbidimetric 
immunoassay, on the  ACL TOP automated analyzer (from Instrumentation Laboratory).  
Normal range for D -dimer levels using these methods are 0 -229 ng/mL.   Plasma HIV 
RNA level will be estimated using COBASÂ® AmpliPrep/COBASÂ® TaqManÂ® HIV -1 Test, 
v2.0.    
 
The following clinical labs will be assessed to monitor for toxicity  per Table 2 above : 
i. Complete Blood Count (CBC, with platelet count and differential)  
ii. Basic Metabolic Panel (B MP) 
iii. Coagulation panel (INR/PT, aPTT, anti -FXa)  
iv. Hepatic Function panel (ALT, AS T, Total bilirubin)  
 
4  SAFETY AND ADVERSE EVENTS  
4.1 Measures to reduce risk for adverse events  
Risks related to edoxaban are principally related to bleeding events .  To reduce this 
risk, p articipants will be counseled to avoid concomitant medications that may increase 
risk for bleeding and be made aware of potential signs/symptoms that may be 
associated with occult bleeding (e.g., dyspepsia, black stools, weakness, fatigue) . 
 
4.2 Adverse Event Definition s 
4.2.1  Adverse Event (AE):   
Any untoward medical occurrence in a clinical research participant administered 
an investigational product , which may or may not have a causal relationship with 
the investigational product. As such, an AE can be an unfavorable or unintended 
sign (including an abnormal laboratory finding, for example), symptom or disease 
temporally associated with the use of an investigational product, whether or not 
considered related to the product.  
 
 Protocol Version 2.0  
 16 If a preexisting condition worsens post -enrollment (frequency increases and/or 
severity grade increases), it should be reported as an adverse event.  
 
A symptom check -list will be included in the CRF (detailed in the protocol 
implementation manual) that includes common symptoms or side effects typically 
related to edoxaban therapy.  
 
Appendix E provides a table of adverse events, with grading criteria, adopted 
from the DAIDS 2009 Table for Grading the Severity of Adult and Pediatric 
Advers e Events  
 
4.2.2  Serious Adverse Event (SAE):   
Any adverse event occurring at any dose that results in any of the following 
outcomes:  
i. Death,  
ii. A life -threatening condition,  
iii. A congenital anomaly/birth defect,  
iv. Inpatient hospitalization or prolongation of existing hospitalization,  
v. Persistent or significant disability/incapacity,  
vi. An important medical event that, based upon appropriate medi cal judgment, 
may jeopardize the patient or subject and may require intervention to 
prevent one of the outcomes listed above.  
4.2.3  Unanticipated Problem (UP) : 
Any event that is:  
i. Unexpected , AND  
ii. Related to study participation in this study , AND  
iii. Increase the ri sk of harm to the participant or others (or be an SAE)  
 
4.3 Documenting Adverse Events  and Unanticipated Problems  
All serious adverse events (SAE) and unanticipated problems (UP) , regardless of the 
assessed relationship with study drug, will be ascertained and recorded on study visit 
CRFs (through the online REDCAP interface).  
 
All new non-serious adverse events of grade â‰¥3 or deemed related to study drug  will be 
ascertained and recorded on study vi sit CRFs (through the online REDCAP  interface). 
Criteria for assigning a grade of severity  of adverse events  are summarized in 
Appendix E.   
 
NOTE:   adverse events based on laboratory criteria will only be 
ascertained/recorded if â‰¥ grade 3, and no adverse events will be 
ascertained/recorded based on CD4+ T -cell count criteria.  
 
 Protocol Version 2.0  
 17 There are five severity grades that can be assigned to adverse events, which are 
defined as follows:  
i. Grade 1 = Mild  
ii. Grade 2 = Moderate  
iii. Grade 3 = Severe  
iv. Grade 4 = Potentially life -threatening  
v. Grade 5 = Death  
 
Addit ional information ascertained for each adverse event includes:  a) date of onset, b) 
relationshi p to study drug (see section 4. 3.1 below ), c) any action taken on study drug, 
and d) whether t he adverse event qualifies as an SAE (including the criteria fulfi lled).  
 
Source documentation (in addition to the CRF variables for AEs) will be collected by 
research coordinators at the clinical site  for all AEs of grade â‰¤3, SAEs or UPs.  
4.3.1  Adverse Event Relationship to Study Drug  
For all adverse event s grade â‰¥3 , SAEs or UPs that occur after randomization , 
study investigator(s) will assess the potential relationship of the event to the 
study medication.  One of the following designations will be used:   
 
i. Related: There is a reasonable possibility that the AE may be related to the 
study agent(s).  
 
ii. Not related: There is not a reasonable possibility that the AE may be related 
to the study agent(s).  Alternative etiology, diagnosis or, explanation for the AE 
should be provided.  
 
4.4 Reporting Serious Adverse Events  and Unanticipated Problems  
The IRB (or Human Subjects Committee ) and the Data Safety Monitoring Board 
(DSMB, see section 5 below) will receive notification of all SAEs that are deemed 
protocol related , or a UP.  NOTE:  an adverse event (of any grade) that is unexpected , is 
reasonably believed to be related to study participation , and involves risk  to the 
participant  or others should be captured as a UP (per definition s above 4.2).   
 
The site will enter information about the SAE/UP event into the appropriate case report 
form (via REDCap reporting).  The data center  can generate a summary of individual, or 
a series of, AE events upon request from the site . 
 
Daiichi Sankyo  will receive notification of all SAEs and/or UPs  within 5  business days of 
learning of the  event .  Reporting of all SAE/UP events will be made to Daiichi Sankyo , 
the FDA (voluntary submission) and the NHLBI P rogram Official  using the same 
reporting information (FDA Form 3500 per below).  Specifically,  sites must:  
 
a) Inform local IRB per institutional guidelines and timelines  
b) fill out a n SAE/UP case report form, via REDCap  online reporting  
 Protocol Version 2.0  
 18 c) fill out an SAE/UP  Form provided by Daiichi Sankyo (APPENDIX F)   
d) email the completed to Daiichi Sankyo  representative  
e) voluntary reporting to FDA, via either submitting  MedWatch Form FDA 3500 or 
complete voluntary reporting online via FDA MedWatch (see below for link)  
 
FDA MedWatch  reporting forms may be found at: 
http://www.fda.gov/safety/medwatch/howtoreport/downloadforms/default.htm  
 
FDA MedWatch  online  voluntary reporting process c an be performed at:  
https://www.accessdata.fda.gov/scripts/medwatch/  
 
The table below summarizes SAE and UP reporting timelines that will be implemented.  
 
Table 3: NHLBI SAE and UP reporting Timelines  
 
What event is 
reported  
 When is Event 
reported  By whom is event 
reported  To whom is Event 
reported  
Fatal or life-
threatening 
unexpected, 
suspected serious 
adverse reactions  Within 7 calendar 
days  of initial receipt 
of information  Investigator  Local IRB  
NHLBI and/or Data 
Coordinating Center  
DSMB  
DSI 
 
Non-fatal, non -life-
threatening 
unexpected, 
suspected serious 
adverse reactions  Within 15 calendar 
days  of initial receipt 
of information  Investigator  Local IRB  
NHLBI and/or DCC  
DSMB  
DSI 
Unanticipated 
Problem that is not an 
SAE Within 14 days  of the 
investigator becoming 
aware of the problem  Investigator  Local IRB  
NHLBI and/or DCC  
DSMB  
 
All Unanticipated 
Problems1 Related or 
Unrelated to study  
 Within 30 days  of the 
IRBâ€™s receipt of the 
report of the UP from 
the investigator.  IRB OHRP2 
NHLBI  
 
1. Per OHRP guidance: only when a particular AE or series of AEs is determined to meet the criteria for an UP should a 
report of the AE(s) be submitted to the IRB at each institution under the HHS regulations at 45 CFR part 46. Such reports 
to the IRB will be submitted by the investigator.  
2. Office for Human Research Protect ions  
 
4.5 Participant Withdrawal  
Participants may withdraw from the study at any time at their request, as described in 
the consent.  All randomized participants  will be encouraged to complete a final study 
visit, including all v isit procedures . 
 
 Protocol Version 2.0  
 19 5 Data and Safety Monitoring  Plan  
The Principal Investigator (PI) will be responsible for ensuring participantsâ€™ safety on a 
daily basis. A Data and Safety Monitoring Board (DSMB) will be formed with Dr. 
Wolfson as the un -blinded statistician; other members will not be part of the study team . 
Committee members will have experience with HIV/AIDS clinical research and 
thrombosis and anticoagulation therapy .  
5.1 Interim  Analysis  
Most of the primary blood and tissue outcomes will not be available until after visits are 
compl eted, as samples will be batch processed at our participating laboratory site. 
Hence, there will be no formal interim analyses for efficacy or futility related to the main 
study outcomes . 
5.2 Frequency and Content of Data and Safety Monitoring  
To ensure compl iance and data are reported correctly and completely, CRF data will be 
monitored monthly for completeness and compliance with the study protocol.  Queries 
for clarification or data completion will be  communicated from the data center to the 
clinical site .  
 
Prior to enrollment the DSMB will review the protocol and data analysis plan.  During 
the study the DSMB will meet at every 6 months, and on an ad -hoc bases as 
necessitated for adverse events . An initial DSMB meeting will be scheduled as soon as 
any of t he following occurs:  
i. Six months have elapsed since enrollment of the first patient  
ii. 50% of goal enrollment is achieved  
iii. 15 participants have completed 1st study drug period (i.e., 4 months)  
  
The data and safety monitoring report will include  data on : enroll ment (including 
progress), visit attendance, completeness of data, completeness and quality of 
specimen collection, baseline characteristics, adherence and discontinuation of 
medication, and side effects and adverse events.   
 
5.2.1  Safety Monitoring by DSMB Officers  
The PI will be informed of all SAEs  deemed protocol related, UPs, or significant 
bleeding events  as soon as they occur and will notify the DSMB for review within 7 
business days of notification.  The two clinicians (one HIV /Medicine  and one 
Hematology) on the DSMB will also serve as medical officers and will perform 
independent safety monitoring for the study.  Indepen dent safety monitoring will  
occur for any of the following:  
ï‚· SAE or UP deemed related  to protocol/study drug  
ï‚· Major ble eding event (ISTH definition in 3.2)  
ï‚· Bleeding event of BARC type â‰¥3 (definition in 3.2 and appendix B)  
 
 Protocol Version 2.0  
 20 Independent safety monitoring will entail a review of a summary report of (de-identified) 
clinical data via email.  The DSMB will then determine whether the study should:  
a) continue and conduct the next scheduled DSMB meeting as planned, or  
b) continue but con duct an additional DSMB call to re -evaluate study safety, or  
c) temporarily stop enrollment, but continue foll ow-up of randomized participants, until 
an additional DSMB meeting can be performed, or  
d) provide more clinical information on the adverse event to properly inform a decision.  
 
As a result of this review a  determination will then be made whether:  a) cont inuing the 
study without change and without additional DSMB review (beyond scheduled meetings 
as planned), b) continue the study but conduct an additional DSMB meeting/call to re -
evaluate study safety, c) temporarily stop enrollment in the study , but conti nue follow -up 
of randomized participants,  until an additional DSMB meeting can be performed to re -
evaluate study safety and appropriateness to continue,  d) more clinical information  is 
needed on the adverse event to properly inform a decision.  
5.3 DSMB (Data a nd Safety Monitoring Board)  
The following individual(s) has/have accepted position(s) as part of the DSMB. Should 
there be any questions regarding the independence of the DSMB, it will be addressed 
and corr ected if necessary at that time.  Julian Wolfson ( lead statistician) will produce 
data reports and represent the protocol team as part of both open and closed sessions 
for the DSMB.   
 
ï‚· Biostatistician: Holly Janes , PhD  (hjanes@fhcrc.org ) 
ï‚· HIV/General Medicine: Matthew Freiberg, MD  
(matthew.s.freiberg@vanderbilt.edu ) 
ï‚· Hematology  Medicine: Sam Schulman, MD ( schulms@mcmaster.ca ) 
ï‚· Hematology Medicine: David Garcia, MD ( davidg99@uw.edu ) 
 
 
The DSMB will monitor progress of the study and safety of the intervention while the 
study is still blinded to the investigators. The frequency of the DSMB monitoring is 
listed above in 5.2.  As part of this responsibility, DSMB members must be satisfied that 
the timeliness, completeness, and accuracy of the data submitted to them for review are 
sufficient for evaluation of the safety and welfare of study participants.   The DSMB will 
also asse ss the performance of the overall study operations and any other relevant 
issues as necessary.  
5.3.1  DSMB Conflict of Interest  and Protection of Confidentiality  
DSMB members  should have no direct involvement with the study investigators 
or intervention. Each DSMB member will sign a Conflict of Interest Statement 
which includes current affiliations, if any, with pharmaceutical and biotechnology 
companies (e.g., stockholder, con sultant), and any other relationship that could 
be perceived as a conflict of interest related to the study and / or associated with 
commercial interests pertinent to study objectives.  
 Protocol Version 2.0  
 21  
Data will be presented in a blinded manner during the open sessions o f the 
DSMB  that include the study PI . At DSMB meetings, data and discussion are 
confidential. Participant identities will not be known to the DSMB members.  
 
5.3.2  DSMB Responsibilities  
The DSMB Charter  provides a detailed list of the DSMB responsibilities. They 
include:  
ï‚· Review the research protocol, informed consent documents and plans for data 
safety and monitoring;  
ï‚· Recommend subject recruitment be initiated after receipt of a satisfactory 
protocol;  
ï‚· Evaluate the progress of the trial, accrual and retention , periodic assessments 
of data quality and timeliness , participant risk versus benefit, and other factors 
that can affect study outcome;  
ï‚· Evaluation of all SAE /UPs, bleeding events of BARC type â‰¥3, and/or major 
bleeding Event (ISTH definition), will be reviewed b y the designed medical 
officers on the DSMB within 1 week of report.  An assessment will be made at 
that time if a full DSMB meeting is required before then next schedule meeting;  
ï‚· Consider factors external to the study when relevant information becomes 
available, such as scientific or therapeutic developments that may have an 
impact on the safety of the participants or the ethics of the trial;  
ï‚· Review study performance, make recommendations and assist in the 
resolution of problems reported by the Principal I nvestigator;  
ï‚· Protect the safety of the study  participants.  
 
6 ANALYSIS PLAN  
The primary analyses involving the main effect of treatment will be performed in an 
intent -to-treat framework using a random effects model with random subject -specific 
intercepts and fixed effects for treatment  period and pre -treatment IL -6 (average of two 
measures, from screening and baseline). Separate models with an interaction term 
between treatment and pre -treatment FXa activity will used to test whether the effect of 
treatment d iffers by the degree of FXa activity (as estimated from computational 
modeling) . The coefficients of the period indicator will be tested to check for evidence of 
treatment sequencing and/or carry -over effects. The characteristics of any patients who 
drop o ut of the study will be compared to the characteristics of those who do not to 
ascertain whether drop -out was informative.   Secondary outcomes will be analyzed in a 
similar fashion to analysis of changes in IL -6. In secondary exploratory analyses, we will 
also perform p er-protocol (â€˜on treatmentâ€™) analyses , as well as imputation and (if 
 Protocol Version 2.0  
 22 necessary) sensitivity analyses to account for missing data. If medication adherence is 
sub-optimal, we will also consider compliance -adjusted analyses.  
We will also use th e IL-6 and D -dimer associations with clinical risk ( Scientific 
Background in 1.1.2. ),63 to estimate the predicted  risk redu ctions for both a composite 
outcome (serious non -AIDS events) as well as individual events such as cardiovascular 
disease  (CVD) events . Statistical tests will include a significance level of alpha=0.05 .
 Protocol Version 2.0  
 23 REFERENCES  
1. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza -Jeric K, 
Hrobjartsson A, Mann H, Dickersin K, Berlin JA, Dore CJ, Parulekar WR, Summerskill 
WS, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D. Spirit 2013 
statement: Defining st andard protocol items for clinical trials. Annals of internal medicine . 
2013  
2. Palella FJ, Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman 
DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced 
human immunod eficiency virus infection. Hiv outpatient study investigators. N Engl J 
Med. 1998;338:853 -860 
3. Mocroft A, Brettle R, Kirk O, Blaxhult A, Parkin JM, Antunes F, Francioli P, D'Arminio 
Monforte A, Fox Z, Lundgren JD. Changes in the cause of death among hiv positive 
subjects across europe: Results from the eurosida study. Aids. 2002;16:1663 -1671  
4. Palella FJ, Jr., Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD. 
Mortality in the highly active antiretroviral therapy era: Changing causes of de ath and 
disease in the hiv outpatient study. J Acquir Immune Defic Syndr . 2006;43:27 -34 
5. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with 
aids in the era of highly active antiretroviral therapy: New york city. Ann Intern M ed. 
2006;145:397 -406 
6. Smit C, Geskus R, Walker S, Sabin C, Coutinho R, Porter K, Prins M. Effective therapy 
has altered the spectrum of cause -specific mortality following hiv seroconversion. Aids. 
2006;20:741 -749 
7. Walensky RP, Paltiel AD, Losina E, Mer cincavage LM, Schackman BR, Sax PE, 
Weinstein MC, Freedberg KA. The survival benefits of aids treatment in the united 
states. J Infect Dis . 2006;194:11 -19 
8. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, Vaeth M, Obel 
N. Survival of persons with and without hiv infection in denmark, 1995 -2005. Ann Intern 
Med. 2007;146:87 -95 
9. Lau B, Gange SJ, Moore RD. Risk of non -aids-related mortality may exceed risk of aids -
related mortality among individuals enrolling into care with cd4+ counts g reater than 200 
cells/mm3. J Acquir Immune Defic Syndr . 2007;44:179 -187 
10. The Antiretroviral Therapy Cohort Collaboration. Causes of death in hiv -1-infected 
patients treated with antiretroviral therapy, 1996 -2006: Collaborative analysis of 13 hiv 
cohort studies. Clin Infect Dis . 2010;50:1387 -1396  
11. Mocroft A, Reiss P, Gasiorowski J, Ledergerber B, Kowalska J, Chiesi A, Gatell J, 
Rakhmanova A, Johnson M, Kirk O, Lundgren J. Serious fatal and nonfatal non -aids-
defining illnesses in europe. Journal of acqu ired immune deficiency syndromes . 
2010;55:262 -270 
12. Crum NF, Riffenburgh RH, Wegner S, Agan BK, Tasker SA, Spooner KM, Armstrong 
AW, Fraser S, Wallace MR. Comparisons of causes of death and mortality rates among 
hiv-infected persons: Analysis of the pre -, early, and late haart (highly active 
antiretroviral therapy) eras. J Acquir Immune Defic Syndr . 2006;41:194 -200 
13. Lewden C, May T, Rosenthal E, Burty C, Bonnet F, Costagliola D, Jougla E, Semaille C, 
Morlat P, Salmon D, Cacoub P, Chene G. Changes in ca uses of death among adults 
infected by hiv between 2000 and 2005: The "mortalite 2000 and 2005" surveys (anrs 
en19 and mortavic). J Acquir Immune Defic Syndr . 2008;48:590 -598 
14. Neuhaus J, Jacobs DR, Jr., Baker JV, Calmy A, Duprez D, La Rosa A, Kuller LH,  Pett 
SL, Ristola M, Ross MJ, Shlipak MG, Tracy R, Neaton JD. Markers of inflammation, 
coagulation, and renal function are elevated in adults with hiv infection. J Infect Dis . 
2010;201:1788 -1795  
 Protocol Version 2.0  
 24 15. Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Pa ge-Shafer K, Hsue P, Emu 
B, Krone M, Lampiris H, Douek D, Martin JN, Deeks SG. Relationship between t cell 
activation and cd4+ t cell count in hiv -seropositive individuals with undetectable plasma 
hiv rna levels in the absence of therapy. J Infect Dis . 200 8;197:126 -133 
16. Crowe SM, Westhorpe CL, Mukhamedova N, Jaworowski A, Sviridov D, Bukrinsky M. 
The macrophage: The intersection between hiv infection and atherosclerosis. J Leukoc 
Biol. 2010;87:589 -598 
17. Sandler N, Wand H, Nixon D, Pedersen C, Ruxrungtham K, Lewin SR, Emery S, Deeks 
SG, Sereti I, Douek D. Plasma levels of soluble cd14 predict mortality in hiv infection. 
17th Conference of Retroviruses and Opportunistic Infections . 2010;Abstract #303  
18. Scherberich JE, Nockher WA. Cd14++ monocytes, cd14+/cd16+ subset and soluble 
cd14 as biological markers of inflammatory systemic diseases and monitoring 
immunosuppressive therapy. Clin Chem Lab Med . 1999;37:209 -213 
19. Walston J, McBurnie MA, Newman A, Tracy  RP, Kop WJ, Hirsch CH, Gottdiener J, Fried 
LP. Frailty and activation of the inflammation and coagulation systems with and without 
clinical comorbidities: Results from the cardiovascular health study. Arch Intern Med . 
2002;162:2333 -2341  
20. Hearps AC, Maisa A, Cheng WJ, Angelovich TA, Lichtfuss GF, Palmer CS, Landay AL, 
Jaworowski A, Crowe SM. Hiv infection induces age -related changes to monocytes and 
innate immune activation in young men that persist despite combination antiretroviral 
therap y. Aids. 2012;26:843 -853 
21. Sodora DL, Silvestri G. Immune activation and aids pathogenesis. Aids. 2008;22:439 -
446 
22. Papagno L, Spina CA, Marchant A, Salio M, Rufer N, Little S, Dong T, Chesney G, 
Waters A, Easterbrook P, Dunbar PR, Shepherd D, Cerundol o V, Emery V, Griffiths P, 
Conlon C, McMichael AJ, Richman DD, Rowland -Jones SL, Appay V. Immune activation 
and cd8(+) t -cell differentiation towards senescence in hiv -1 infection. PLoS Biol . 
2004;2:E20  
23. Weissman D, Barker TD, Fauci AS. The efficiency o f acute infection of cd4+ t cells is 
markedly enhanced in the setting of antigen -specific immune activation. J Exp Med . 
1996;183:687 -692 
24. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, Okamoto Y, Casazza JP, 
Kuruppu J, Kunstman K, Wolinsky S, G rossman Z, Dybul M, Oxenius A, Price DA, 
Connors M, Koup RA. Hiv preferentially infects hiv -specific cd4+ t cells. Nature . 
2002;417:95 -98 
25. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover 
of plasma virions and cd4 lymphocy tes in hiv -1 infection. Nature . 1995;373:123 -126 
26. Schacker T. The role of secondary lymphatic tissue in immune deficiency of hiv infection. 
Aids. 2008;22 Suppl 3:S13 -18 
27. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, 
Bornstein E, Lambotte O, Altmann D, Blazar BR, Rodriguez B, Teixeira -Johnson L, 
Landay A, Martin JN, Hecht FM, Picker LJ, Lederman MM, Deeks SG, Douek DC. 
Microbial translocation is a cause of systemic immune activation in chronic hiv infection. 
Nat Med . 2006 ;12:1365 -1371  
28. Naeger DM, Martin JN, Sinclair E, Hunt PW, Bangsberg DR, Hecht F, Hsue P, McCune 
JM, Deeks SG. Cytomegalovirus -specific t cells persist at very high levels during long -
term antiretroviral treatment of hiv disease. PLoS One . 2010;5:e8886  
29. Hunt PW, Martin JN, Sinclair E, Epling L, Teague J, Jacobson MA, Tracy R, Corey L, 
Deeks SG. Valganciclovir reduces t cell activation in treated hiv infection. Journal of 
Infectious Diseases . 2011; (in press)  
 Protocol Version 2.0  
 25 30. Estes J, Baker JV, Brenchley JM, Khoruts A, Barthold JL, Bantle A, Reilly CS, Beilman 
GJ, George ME, Douek DC, Haase AT, Schacker TW. Collagen deposition limits 
immune reconstitution in the gut. J Infect Dis . 2008;198:456 -464 
31. Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on he alth during 
chronic hiv infection. Immunity . 2013;39:633 -645 
32. Rajasuriar R, Khoury G, Kamarulzaman A, French MA, Cameron PU, Lewin SR. 
Persistent immune activation in chronic hiv infection: Do any interventions work? Aids. 
2013;27:1199 -1208  
33. Baker JV , Brummel -Ziedins K, Neuhaus J, Duprez D, Cummins N, Dalmau D, Dehovitz 
J, Lehmann C, Sullivan A, Woolley I, Kuller L, Neaton JD, Tracy RP, Team ISS. Hiv 
replication alters the composition of extrinsic pathway coagulation factors and increases 
thrombin gen eration. J Am Heart Assoc . 2013;2:e000264  
34. Baker JV, Huppler Hullsiek K, Bradford RL, Prosser R, Tracy RP, Key NS. Circulating 
levels of tissue factor microparticle procoagulant activity are reduced with antiretroviral 
therapy and are associated with pe rsistent inflammation and coagulation activation 
among hiv -positive patients. J Acquir Immune Defic Syndr . 2013;63:367 -371 
35. Xu J, Lupu F, Esmon CT. Inflammation, innate immunity and blood coagulation. 
Hamostaseologie . 2010;30:5 -6, 8-9 
36. Delvaeye M, Co nway EM. Coagulation and innate immune responses: Can we view 
them separately? Blood . 2009;114:2367 -2374  
37. Sutherland MR, Ruf W, Pryzdial EL. Tissue factor and glycoprotein c on herpes simplex 
virus type 1 are protease -activated receptor 2 cofactors that enhance infection. Blood . 
2012;119:3638 -3645  
38. Antoniak S, Owens AP, 3rd, Baunacke M, Williams JC, Lee RD,  Weithauser A, Sheridan 
PA, Malz R, Luyendyk JP, Esserman DA, Trejo J, Kirchhofer D, Blaxall BC, Pawlinski R, 
Beck MA, Rauch U, Mackman N. Par -1 contributes to the innate immune response 
during viral infection. J Clin Invest . 2013;123:1310 -1322  
39. Funderb urg NT, Mayne E, Sieg SF, Asaad R, Jiang W, Kalinowska M, Luciano AA, 
Stevens W, Rodriguez B, Brenchley JM, Douek DC, Lederman MM. Increased tissue 
factor expression on circulating monocytes in chronic hiv infection: Relationship to in 
vivo coagulation and  immune activation. Blood . 2010;115:161 -167 
40. Armah KA, McGinnis K, Baker J, Gibert C, Butt AA, Bryant KJ, Goetz M, Tracy R, 
Oursler KA, Rimland D, Crothers K, Rodriguez -Barradas M, Crystal S, Gordon A, 
Kraemer K, Brown S, Gerschenson M, Leaf DA, Deeks S G, Rinaldo C, Kuller LH, 
Justice A, Freiberg M. Hiv status, burden of comorbid disease and biomarkers of 
inflammation, altered coagulation and monocyte activation. Clin Infect Dis . 2012;55:126 -
136 
41. Ford ES, Greenwald JH, Richterman AG, Rupert A, Dutcher  L, Badralmaa Y, Natarajan 
V, Rehm C, Hadigan C, Sereti I. Traditional risk factors and d -dimer predict incident 
cardiovascular disease events in chronic hiv infection. Aids. 2010;24:1509 -1517  
42. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane H C, Ledergerber B, 
Lundgren J, Neuhaus J, Nixon D, Paton NI, Neaton JD. Inflammatory and coagulation 
biomarkers and mortality in patients with hiv infection. PLoS Med . 2008;5:e203  
43. Pandrea I, Cornell E, Wilson C, Ribeiro RM, Ma D, Kristoff J, Xu C, Haret -Richter GS, 
Trichel A, Apetrei C, Landay A, Tracy R. Coagulation biomarkers predict disease 
progression in siv -infected nonhuman primates. Blood . 2012;120:1357 -1366  
44. Hart D, Sayer R, Miller R, Edwards S, Kelly A, Baglin T, Hunt B, Benjamin S, Patel R, 
Machin S, Scully M. Human immunodeficiency virus associated thrombotic 
thrombocytopenic purpura --favourable outcome with plasma exchange and prompt 
initiation of highly active antiretroviral therapy. Br J Haematol . 2011;153:515 -519 
 Protocol Version 2.0  
 26 45. Riewald M, Ruf W. Orchestration of coagulation protease signaling by tissue factor. 
Trends Cardiovasc Med . 2002;12:149 -154 
46. Chambers RC. Procoagulant signalling mechanisms in lung inflammation and fibrosis: 
Novel opportunities for pharmacological interv ention? Br J Pharmacol . 2008;153 Suppl 
1:S367 -378 
47. Coughlin SR. Thrombin signalling and protease -activated receptors. Nature . 
2000;407:258 -264 
48. Riewald M, Kravchenko VV, Petrovan RJ, O'Brien PJ, Brass LF, Ulevitch RJ, Ruf W. 
Gene induction by coagula tion factor xa is mediated by activation of protease -activated 
receptor 1. Blood . 2001;97:3109 -3116  
49. Camerer E, Huang W, Coughlin SR. Tissue factor - and factor x -dependent activation of 
protease -activated receptor 2 by factor viia. Proceedings of the Na tional Academy of 
Sciences of the United States of America . 2000;97:5255 -5260  
50. Rao LV, Pendurthi UR. Tissue factor -factor viia signaling. Arterioscler Thromb Vasc Biol . 
2005;25:47 -56 
51. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of c -reactive protein and 
low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. 
N Engl J Med . 2002;347:1557 -1565  
52. Danesh J, Kaptoge S, Mann AG, Sarwar N, Wood A, Angleman SB, Wensley F, Higgins 
JP, Lennon L, Eiriksdottir G, Rumley A, Whincup PH, Lowe GD, Gudnason V. Long -term 
interleukin -6 levels and subsequent risk of coronary heart disease: Two new prospective 
studies and a systematic review. PLoS Med . 2008;5:e78  
53. Ridker PM, Hennekens CH, Buring JE, Rifai N. C -reactiv e protein and other markers of 
inflammation in the prediction of cardiovascular disease in women. N Engl J Med . 
2000;342:836 -843 
54. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentrations of interleukin -
6 and the risk fo future myocardial inf arction among apparently healthy men. Circulation . 
2000;101:1767 -1772  
55. Neuhaus J, Jacobs DR, Baker JV, Calmy A, Duprez D, La Rosa A, Kuller LH, Pett S, 
Ristola M, Ross MJ, Shlipak MG, Tracy R, Neaton JD, for the INSIGHT SMART 
MaCRG. Markers of inflammation, coagulation, and renal function in hiv -infected adults 
in smart and i n two large population -based cohorts. Journal of Infectious Diseases . 
2010; in press  
56. Tien PC, A.I. C, A.R. Z, C. B, Scherzer R, Bacchetti P, Shlipak M, Grunfeld C. 
Inflammation and mortality in hiv -infected adults:  Analysis of the fram study cohort. 17th 
Conference on Retroviruses and Opportunistic Infections (CROI) . 2010;Abstract #725  
57. Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, Pedersen C, 
Ruxrungtham K, Lewin SR, Emery S, Neaton JD, Brenchley JM, Deeks SG, Sereti I, 
Douek DC. Plasma le vels of soluble cd14 independently predict mortality in hiv infection. 
J Infect Dis . 2011;203:780 -790 
58. Triant VA, Meigs JB, Grinspoon SK. Association of c -reactive protein and hiv infection 
with acute myocardial infarction. J Acquir Immune Defic Syndr . 2009;51:268 -273 
59. Kaplan RC, Sinclair E, Landay AL, Lurain N, Sharrett AR, Gange SJ, Xue X, Hunt P, 
Karim R, Kern DM, Hodis HN, Deeks SG. T cell activation and senescence predict 
subclinical carotid artery disease in hiv -infected women. J Infect Dis . 201 1;203:452 -463 
60. Duprez D, Neuhaus J, Kuller L, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, 
Ledergerber B, Lundgren J, Nixon D, Paton NI, Prineas R, Neaton JD. Inflammation, 
coagulation and cardiovascular disease in hiv -infected individuals PLoS On e. 2012; in 
press  
61. Borges A, Silverberg MJ, Wentworth D, Grulich AE, Fatkenheuer G, Mitsuyasu R, 
Tambussi G, Sabin C, Neaton J, Lundgren J, Group ftISESS. Predicting risk of cancer 
 Protocol Version 2.0  
 27 during hiv infection: The role of inflammation and coagulation biomarkers . 14th 
International Workship on Co -morbidities and Adverse Drug Reactions in HIV . 2012  
62. Duprez DA, Neuhaus J, Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane 
HC, Ledergerber B, Lundgren J, Nixon D, Paton NI, Prineas RJ, Neaton JD, Group ISS. 
Inflammation, coagulation and cardiovascular disease in hiv -infected individuals. PLoS 
One. 2012;7:e44454  
63. Grund B, Baker J, Deeks SG, Wolfson J, Wentworth D, Cozzi -Lepri A, Cohen C, Phillips 
A, Lundgren J, Neaton J, INSIGHT SMART/ESPRIT/SILCAAT Study G roups. Combined 
effect of interleukin -6 and d -dimer on the risk of serious non -aids conditions:  Data from 
3 prospective cohorts. 20th Conference on Retroviruses and Opportunistic Infections . 
2013;#60  
64. Borges AH, Silverberg MJ, Wentworth D, Grulich AE, Fatkenheuer G, Mitsuyasu R, 
Tambussi G, Sabin CA, Neaton JD, Lundgren JD, for the Insight Smart ESSG. 
Predicting risk of cancer during hiv infection: The role of inflammatory and coagulation 
biomarkers. Aids. 2013;27:1433 -1441  
65. Harris TB, Ferrucci L, Tr acy RP, Corti MC, Wacholder S, Ettinger WHJ, Heimovitz H, 
Cohen HJ, Wallace R. Associations of elevated interleukin -6, c-reative protein levels with 
mortality in the elderly. American Journal of Medicine . 1999;106:506 -512 
66. Folsom AR, Delaney JA, Lutsey PL, Zakai NA, Jenny NS, Polak JF, Cushman M. 
Associations of factor viiic, d -dimer, and plasmin -antiplasmin with incident cardiovascular 
disease and all -cause mortality. Am J Hematol . 2009;84:349 -353 
67. Camm AJ, Bounameaux H. Edoxaban: A new oral direct f actor xa inhibitor. Drugs . 
2011;71:1503 -1526  
68. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, 
Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, 
Grip LT, Patel SP, Patel I, Hanyok JJ, Me rcuri M, Antman EM, Investigators EA -T. 
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med . 
2013;369:2093 -2104  
69. Hokusai VTEI, Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, 
Raskob GE, Schellong SM, Schwocho  L, Segers A, Shi M, Verhamme P, Wells P. 
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N 
Engl J Med . 2013;369:1406 -1415  
70. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the S, 
Standardization Comm ittee of the International Society on T, Haemostasis. Definition of 
major bleeding in clinical investigations of antihemostatic medicinal products in non -
surgical patients. J Thromb Haemost . 2005;3:692 -694 
71. Baker JV, Huppler Hullsiek K, Singh A, Wilson EM, Henry K, LIchtenstein K, Onen N, 
Kojic E, Patel P, Brooks JT, Hodis H, Budoff M, Sereti I, for the CDC SUN Study 
Investigators. Immunologic predictors of coronary artery calcium progression in a 
contemporary hiv cohort. Aids. 2014;28  
72. Panel on Antir etroviral Guidelines for Adults and Adolescents. Guidelines for the use of 
anti-retroviral agents in hiv -1-infected adults and  
adolescents. 2013;Available at:  
http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf  
 
 
 Protocol Version 2.0  
 1 APPENDIX A:  BLOOD S PECIMEN COLLECTION A ND STORAGE     
             Updated: April 2015  
 
 CLINICAL  Blood Collection Tube  Blood Volume  S B M1 M2 M3 M4 M7 M8 M9 M10  M11  M12  HCMC Labs Processing  HIV RNA  (1) 4ml EDTA  Lavender  2-3mL  X* X X X X X  X X X X X 
CD4 Cou nt + CBC  (1) 4ml EDTA  Lavender  4mL   X    X  X    X 
CBC 2-3mL  X*  X X X    X X X  
BMP, Hepatic Panel  (1) 5mL  Green  4mL  X* X X   X  X X   X 
Lipid Panel   X           
INR, aPTT  
(1) 5mL NaCitrate Blue  4mL  X* X X X X X  X X X X X 
D-Dimer  X*            
Anti-Xa  X    X  X    X 
HBsAg & HCV Ab  (1) 5mL SST Red  4mL   X*      X* X X X X 
  Pregnancy, Urine    X  X X X X  X X X X X 
  Core 
Labs  BLOOD FOR 
STORAGE   Blood 
Vol Cryo 
Vials 
** S B M1 M2 M3 M4 M7 M8 M9 M10  M11  M12   
Study Lab Processing  NIH PBMC  
(Processing at UMN)  (4) 10mL CPT Tiger Top  36mL  3  X X   X  X X   X 
UNC  Platelet Free Plasma  (3) 5mL NaCitrate Blue  15mL  4 X      X      
15mL  8  X X X X X  X X X X X 
Whole blood 
storage  [5mL Na -Citrate Blue ] 5mL  4 X X X X X X X X X X X X 
UVT  Serum  5mL SST Red  5mL  1 X      X      
5mL  3  X X X X X  X X X X X 
Platelet Poor Plasma  10mL EDTA Lavender  10mL  3 X      X      
10mL  7  X X X X X  X X X X X 
  *Labs values from anytime within 30days of screening can be used; previously positive hepatitis labs (i.e., HBsAg or HCV Ab) d o not need to be 
repeated  
**Vials  are to be 500 Î¼l Full  
[ ] Aliquot  prior to plasma processing    
 Protocol Version 2.0  
 2 APPENDIX B :  BLEEDING ACADEMIC RESEARCH CO NSORTIUM 
(BARC) DEFINITIONS  
 
Type 0  no bleeding  
Type 1  bleeding that is not actionable and does not cause the patient to seek 
unscheduled performance of studies, hospitalization, or treatment by a 
healthcare professional; may include episodes leading to self -discontinuation of 
medical therapy by the patient wi thout consulting a healthcare professional  
Type 2  any overt, actionable sign of hemorrhage (e .g., more bleeding than would be 
expected for a clinical circumstance, including bleeding found by imaging 
alone) that does not fit the criteria for type 3, 4, or 5 but does meet at least one 
of the following criteria: (1) requiring nonsurgical, medical intervention by a 
healthcare professional, (2) leading to hospitalization or increased level of care, 
or (3) prompting evaluation  
Type 3  Type 3a  
ï‚· Overt bleeding plus hemoglobin drop of 3 -<5 g/dL  (provided hemoglobin 
drop is related to bleed)  
ï‚· Any transfusion with overt bleeding  
 
Type 3b  
ï‚· Overt bleeding plus hemoglobin drop â‰¥5 g/dL  (provided hemoglobin 
drop is related to bleed)  
ï‚· Cardiac tamponade  
ï‚· Bleeding requiring surgical intervention for control (excluding 
dental/nasal/skin/hemorrhoid)  
ï‚· Bleeding requiring intravenous vasoactive agents  
 
Type 3c  
ï‚· Intracranial hemorrhage (does not include microbleeds or hemorrhagic 
transformation, does include intraspinal)  
ï‚· Subcategories confirmed by autopsy or imaging or lumbar puncture  
ï‚· Intraocular bleed compromising vision  
 
Type 4  CABG -related bleeding (cardiac surgery)  
ï‚· Perioperative intracranial bleeding within 48 hours  
ï‚· Reoperation after closure of sternotomy for the purpose of controlling 
bleeding  
ï‚· Transfusion of â‰¥5 U whole blood or packe d red blood cells within a 48 -
hour period  
ï‚· Chest tube output â‰¥2 L within a 24 hour period  
 
 
  
 Protocol Version 2.0  
 3 APPENDIX C:  CLINICAL MANAGEM ENT OF FACTOR X INHI BITOR 
BLEEDING EVENTS  
 
NOTE:   TACTICAL -HIV participants the present with acute or active bleeding complication during 
the course of the study should be referred for clinical evaluation at the appropriate or nearby health 
care facility.  Management of clinical bleeding complications w ill not be directed by the TACTICAL -
HIV study team, and will be supported by the participantâ€™s health insurance or third -party payer . 
 
There is no specific reversal agent or pharmacologic antidote  to edoxaban -related bleeding , thus 
management of hemorrhagi c complications is primarily supportive. Edoxaban is moderately protein 
bound (e.g., 5 0-60%) and is not dialyzable. If patients require pharmacologic therapy to manage 
hemorrhagic c omplications, a Hematology/ Coagulation consult is advised.   
 
A FXa -activity level can is available by most clinical labs (and at HCMC), which can provide 
information quickly on the degree of FXa inhibition.  The table below summarizes o ne approach to 
management of Factor Xa inhibitor -related bleeding events , adapted  from University of North 
Carolina Anticoagulation Reversal Guidelines : 
www.med.unc.edu/emergmed/files/emergent -anticoagulation -reversal -in-the-ed 
 
Bleeding Severity  Management Approach  
Mild Delay next dose or discontinue Factor Xa inhibitor  
Moderate  Consider any of the following based on bleeding severity:  
ï‚· Symptomatic treatment  
ï‚· Mechanical compression  
ï‚· Surgical intervention  
ï‚· Fluid replacement and hemodynamic support  
ï‚· Blood product transfusion  
ï‚· Oral activated charcoal  (if previous dose ingested within 2 hours)  
   Dose: Liquid charcoal with sorbitol 50 g PO x 1 dose  
 
If hemostasis is not achieved with the strategies outlined above, proceed to 
the steps below and obtain a Hematology/Coagulation consult for further 
recommendations  
Severe or Life -
Threatening   
Consider any of the strategies outlined above based on bleeding severity. 
No agent currently available in the US  has been shown to successfully 
reverse the anticoagulant effects of Factor Xa inhibitor -related bleeding 
events. However, the strategy below may be considered based on the 
currently available evidence. Therefore, the pharmacologic interventions 
below may be considered, but are not required in the management of 
Factor Xa inhibitor -related bleeding.  
A Hematology/Coagulation consult should be obtained after the following:  
1) Administer KCentra (4 -factor PCC) 50 units/kg IV x 1 (max 5000 units)  
2) For persi stent refractory bleeding, pursue formal Heme/Coag consult.  
3) To investigate potential causes of the bleeding event, obtain the 
following: serum creatinine, PT, aPTT, anti -Xa activity (send -out lab), CBC 
(platelets).  
4) If PT prolonged, administer vitam in K 10mg IV x one dose (as there may 
be vitamin K deficiency present).  
 
Table adapted from Eerenberg, Circulation 2011 (Oct 4);124(14):1573 -1579  
 
  
 Protocol Version 2.0  
 4  
APPENDIX D:  DEFINITION AND CRITE RIA FOR AIDS EVENT  
The following list encompass the CDC's 1993 surveillance case definition of AIDS (without 
the CD4+ criterion), with the addition of several diagnoses increasingly felt to be associated 
with severe immunosuppression in participants infected with HIV.  
 
Modi fied CDC Category C 1993 Definition  
â€¢ Candidiasis of bronchi, trachea or lungs  
â€¢ Candidiasis, esophageal  
â€¢ Cervical cancer, invasive  
â€¢ Coccidioidomycosis, disseminated or extrapulmonary  
â€¢ Cryptococcosis, extrapulmonary  
â€¢ Cryptosporidiosis, chronic intestinal (> 1 monthâ€™s duration)  
â€¢ CMV disease (other than liver, spleen, or nodes)  
â€¢ CMV retinitis (with loss of vision)  
â€¢ Encephalopathy, HIV -related (including AIDS Dementia Complex)  
â€¢ Herpes simplex , chronic ulcers (> 1 mo); or bronchitis, pneumonitis  or esophagitis  
â€¢ Histoplasmosis, disseminated or extrapulmonary  
â€¢ Isosporiasis, chronic intestinal (> 1 monthâ€™s duration)  
â€¢ Kaposiâ€™s sarcoma (mucocutaneous or visceral)  
â€¢ Lymphoma, Burkittâ€™s (or equivalent term)  
â€¢ Lymphoma, primary, of brain  
â€¢ Mycobacteri um avium complex or M. kansasii , disseminated or extrapulmonary  
â€¢ M. tuberculosis , any site (pulmonary or extrapulmonary)  
â€¢ Mycobacterium , other species or unidentified species, disseminated or extrapulmonary  
â€¢ Pneumocystis carinii pneumonia ( pneumocystic jiroveci ) 
â€¢ Pneumonia, recurrent ba cterial (2 episodes within 1 y r of each other , after  randomization)  
â€¢ Progressive multifocal leukoencephalopathy  
â€¢ Salmonella sepsis, recurrent (2  episodes within 1 year of each other , after randomization)  
â€¢ Toxoplasmosis  of brain  
â€¢ Wasting syndrome due to HIV  
 
Additions to CDC Definition  
â€¢ Aspergillosis, invasive  
â€¢ Bartonellosis  
â€¢ Chagas disease (American trypanosomiasis) of the CNS  
â€¢ Herpes zoster , multi -dermatomal (â‰¥10 lesions in a non -contiguous site)  
â€¢ Leishmaniasis, visceral (kala -azar)  
â€¢ Lymphoma, Hodgkinâ€™s  
â€¢ Lymphoma, non -Hodgkin's, all cell types  
â€¢ Microsporidiosis (> 1 monthâ€™s duration)  
â€¢ Nocardiosis  
â€¢ Penicillium marneffii , disseminated  
â€¢ Pneumocystis carinii , extrapulmonary  
â€¢ Rhodococcus equi disease  
  
 Protocol Version 2.0  
 5  
APPENDIX E:  ADVERSE EVENT S GRADING TA BLES (FROM 
NIH/DAIDS)   
 
  
 
 
 
 
 
 
Divisio n of AIDS (DAIDS) Table for 
Grading the Severity of Adult and 
             Pediatric Adverse Events   
  
 
 
Version 2.0 
November 201 4 
 
 
MODIFIED FOR TACTICAL -HIV STUDY (PCC008)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Division of AIDS 
National Institute of Allergy and Infec tious Diseases 
National Institutes of He alth 
US Department of Health and Hu man Ser vices
 
 Table of Contents 
 
Gloss ary and Acronyms ..................................................................................................................  1 
 
Introduction............................................................................................................................. ........ 3 
 
Instructions for Use .........................................................................................................................  4 
Major Clinical Conditio ns...............................................................................................................  7 
 
Cardiovascular ..........................................................................................................................  7 
 
Dermatologic.............................................................................................................................  9 
Endo crine and Metabolic  ........................................................................................... .............  10 
 
Gastrointestinal .......................................................................................................................  11 
 
Musculosk eletal ......................................................................................................................  13 
Neurologic............................................................................................................................ ... 14 
 
Pregnancy, Puerperium, and Perinatal ....................................................................................  16 
 
Psychiatric ............................................................................................................................. .. 17 
Respiratory ............................................................................................................................. . 18 
 
Sensory...................................................................................................................... ..............  19 
 
Systemic ............................................................................................................................. ..... 20 
Urinary ...................................................................................... ..............................................  22 
 
Site Reactions to  Injections and Infusions  ....................................................................................  23 
Laboratory Values.........................................................................................................................  24 
 
Chemistries .............................................................................................................................  24 
 
Hematology.................................................................................................................... .........  27 
Urinalysis ............................................................................................................................. ... 29 
 
Appendix A.  Tot al Bilirubin T able for Term and Preterm Neonates ..........................................  30
DAIDS AE Gradin g Table Version 2.0- Nov ember 2014 
Page 1  
 Glossary and Acronyms 
 
AE Adverse event; Any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally 
associated  with the use of a medical treatment or procedure regardless 
of whether it is considered related  to the medical treatment or 
procedure. 
ALT (SGPT)                                                  Alanine aminotransferase (serum glutamic pyruvic transaminase) 
 ANC                                                               Absolute neutrophil count   
AST (SGO T)                                                  Aspartate aminotransferase (serum glutamic-oxaloacetic  transaminase) 
 AV                                                                  Atrioventricular   
Basic Self-care Functions                              Adult 
Activities such as bathing, dressing, toileting, transfer or movement, 
continence, and feeding. 
 
Young Children 
Activities that are age and culturally appropr iate, such as feeding oneâ€™s 
self with culturally appropr iate eating implements. 
BMI z-score                                                   Body mass index z- score; A body reference norm. Specifically, the 
number of standard deviations a participant's BMI differs from the 
average BMI for their age, sex, and ethnicity. 
BMD t-score                                                  Bone mineral density t-score; The number of standard deviations above 
or below the mean bone mineral density of a healthy 30 year old adult 
of the same sex and ethnicity as the participant. 
BMD z-score                                                  Bone mineral density z-score; The number of standard deviations a 
participant's BMD differs from the average BMD for their age, sex, and 
ethnicity. 
BPAP                                                             Bilevel positive airway pressure; A mode used during noninvasive 
positive pressure ventilation. 
Chemical Pregnancy                                      A pregnancy in which a positive pregnancy test is followed by a 
negative pregnancy test without evidence of a clinical pregnancy loss. 
CNS                                                                Central nervous system 
CPAP                                                             Continuous positive airway pressure 
DAERS                                                          DAIDS Adverse Experience Reporting System; An internet-based 
system developed for clinical research sites to report Expedited 
Adverse Events (EAEs) to DAIDS. It facilitates  timely EAE report 
submission and serves as a centralized  location for accessing and 
processing EAE information for reporting purposes. 
Disability                                                        A substantial disruption of a personâ€™s ability to conduct normal life 
functions. 
ECG                                                               Electrocardiogram 
 eGFR                                                              Estimated glomerular filtration rate   
Hospitalizati on                                                Does not include the following hospital admissions: under 24 hours, 
unrelated  to an  adverse event (e.g., for labor and delivery, cosmetic 
surgery, social or administrative for temporary placement [for lack of a 
place to sleep]), protocol-specified, and for diagnosis or therapy of a 
condition that existed before the receipt of a study agent and which has 
not increased in severity or frequency. 
 INR                                                                 International normalized  ratio  
DAIDS AE Gradin g Table Version 2.0- Nov ember 2014 
Page 2  
 Glossary and Acronyms   
 
Intervention                                                    Medical, surgical, or other procedures recommended or provided by a 
healthcare professional for the treatment of an adverse event. 
 IV                                                                   Intravenous   
IVIG                                                                Intravenous immune globulin 
 LDL                                                                Low density lipopro tein   
LLN                                                                Lower limit of normal 
Life-threatening AE                                       Any adverse event that places  the participant, in the view of the 
investigator, at immediate risk of death from the reacti on when it 
occurred (i.e., it does not include a reacti on that would have caused 
death if it had occurred in a more severe form). 
NA                                                                  Not applicable 
Participant ID                                                 The identification number assigned to a study participant which is used 
to track study-related  documentation, including any reported AEs. 
PR Interval                                                     The interval between the beginning of the P wave and the beginning of 
the QRS complex of an elect rocardiogram that represents the time 
between the beginning of the contraction of the atria and the beginning 
of the contraction of the ventricles. 
 PT                                                                   Prothrombin time   
PTT                                                                 Partial thromboplastin time 
QTc Interval                                                  The measure of time between the onset of ventricular depolarization 
and completion of ventricular repolarization corrected  for ventricular 
rate. 
RBC                                                               Red blood cell 
 SI                                                                    Standard international unit   
ULN                                                                Upper limit of normal 
Usual Social & Functional Activities            Activities which adults and children perform on a routine basis and 
those which are part of regular activities of daily living, for example: 
 
Adult 
Adaptive tasks and desirable activities, such as going to work, 
shopping, cooking, use of transportation, or pursuing a hobby. 
 
Young Children 
Activities that are age and culturally appropr iate, such as social 
interactions, play activities, or learning tasks. 
WBC                                                              White blood cell 
 WHO                                                              World Health  Organization   
WNL                                                               Within normal limits
DAIDS AE Gradin g Table Version 2.0- Nov ember 2014 
Page 3  
 Introduction 
 
The Division of  AIDS (DAIDS) oversees clinical trials throughout the  world whi ch it sponso rs 
and suppo rts.  The  clinical trials evaluate the safety and efficacy of therapeutic products, 
vaccines, and oth er preventive  modalities.  Adv erse event (AE) data collected during th ese 
clinical trials form the  basis for subsequent safety and efficacy analyses of pharmaceutical 
products and m edical devices.  Incorrect and in consistent AE s everity grading can lead to 
inaccurate data analyses and int erpretation, whi ch in turn can imp act the safety and w ell-being of 
clinical trial participants and future patients using ph armaceutical products. 
 
The DAIDS AE grading table is a shared tool for assessing  the severity of AEs (including 
clinical and laboratory abnormalities) in participants enrolled in clinical trials.  Ov er the years as 
scientific knowl edge and experience have expanded, revisions to the  DAIDS AE grading table 
have become necessary. 
 
This document is for use in PCC008 (TACTICAL -HIV).  Instructions and information related to 
pediatric events and microbicide studies have been removed from the 2014 clarification of the 
DAIDS Table for Grading AEâ€™s.   Thus, all definitions pertain to adults (â‰¥ÃŸ18 years old)  
DAIDS AE Gradin g Table Version 2.0- Nov ember 2014 
Page 4  
 Instructions for Use 
 
General Co nsiderations 
The Division of A IDS (DAIDS) Table for Grading the  Severity of Adult and  Pediatric  Adverse 
Events, V ersion 2.0 consists of  parameters, or AEs, with s everity grading guid ance that are to be 
used in D AIDS clinical trials for safety data reporting to maintain accuracy and consist ency in 
the evaluation of  AEs.  The term â€œsevereâ€ is not the  same as the term â€œseriousâ€  in classifying 
AEs.  The  severity of a specific event describes its int ensity, and it is the  intensity which is 
graded.  Seriousness, whi ch is not graded, relates to an out come of an AE and is a  regulatory 
definition.  
 
Clinical sites are encouraged to report parameters in the  DAIDS AE grading table as they are 
written to m aintain data consist ency across clinical trials.  How ever, since some parameters can 
be reported with mo re specificity, clinical sites are encouraged to report parameters that convey 
addition al clinical information.  For example, diarrhea could be  reported as neonatal diarrhea; 
seizures, as febrile seizures; and pain, as jaw pain. 
 
The DAIDS AE grading table provides an AE severity grading scale ranging from g rades 1 to 5 
with d escriptions for each AE b ased on the  following general guidelines: 
â€¢   Grade 1 indi cates a mild event 
â€¢   Grade 2 indi cates a moderate event 
â€¢   Grade 3 indi cates a severe event 
â€¢   Grade 4 indi cates a potentially life-threatening event 
â€¢ Grade 5 indi cates death (Note: This grade is not sp ecifically listed on each page of the 
grading table). 
 
Other points to consid er include: 
â€¢   Use parameters defined by age and sex values as applicable. 
â€¢   Male and female sex are defined as sex at birth. 
â€¢ Unless not ed, laboratory values are for term neonates.  Preterm neonates should be  assessed 
using  local laboratory normal ranges. 
â€¢   Where applicable, Standard International (SI) units are included in it alics. 
 
Selecting and Reporting a Primary AE  Term 
When selecting a  primary AE term to report, sites should s elect the term that best describes what 
occurred to the  participant.  For example, a participant may present with it ching, urticaria, 
flushin g, angioedema of the face, and dyspnea.  If the underlying diagnosis is d etermined to be 
an acute allergic reaction, sit es should report â€œAcute Allergic Reactionâ€  as the primary AE term. 
 
Primary AE terms should be  reported using  the DAIDS Adverse Experience Reporting System 
(DAE RS) only if they meet expedited reporting criteria.  Ho wever, all primary AE terms should 
be reported using  protocol-specific case report forms (CRFs).  Because the reported information 
is sto red in di fferent databases (i.e., safety and clinical), sites should report primary AE terms 
using  the same terminolo gy for data consist ency.
DAIDS AE Gradin g Table Version 2.0- Nov ember 2014 
Page 5 Instructions for Use    
  
When reporting using DAERS, other clinically significant events associated with a  primary AE 
term that more fully describe the nature, severity, or compli cations of  the primary AE term 
should be  entered in the  â€œOther Eventsâ€ section.  How ever, the severity grade for these events 
must be  lower than or equal to the severity grade of the primary AE term.  In the  example  above, 
dyspnea and angioedema of the face may be entered in the â€œOther Eventsâ€ section, b ecause they 
are more descriptive  and provide  addition al information on the  severity of the acute allergic 
reaction.  H owever, their severity grades must be  lower than or equal to the  severity grade of the 
primary AE term of â€œAcute Allergic Reactionâ€. 
 
Differences exist in the  reporting and recording of information (e.g., signs and symptoms, 
clinically significant events) in DAE RS and CRFs.  Th erefore, sites shou ld refer to their 
protocols and CRF requirements for further instructions.  
 
Grading Adult and Pediatric AEs 
When a single parameter is not appropriate for grading an AE in both adult and pediatric 
popul ations, s eparate parameters with sp ecified age ranges are provided.  If no distin ction 
between adult and pediatric popul ations h as been made, the listed parameter should be  used for 
grading an AE in both p opulations.  
 
Reporting Pregnancy Outcomes 
In the  Pregnan cy, Puerperium, and P erinatal section, all parameters are pregnancy outcomes 
and should be  reported using the moth er's participant ID.  If an infant is not enrolled in the  same 
study as the moth er, any identified birth defects should be  reported usi ng the moth er's participant 
ID.  How ever, if an infant is enrolled in the  same study as the moth er or in another study, any 
identified birth defects should be  reported usi ng the infant's participant ID.  Sites should refer to 
the applicable network standards for reporting abnormal pregnancy outcomes on the  CRFs. 
 
Determining Severity Grade for Parameters between Grades 
If the severity of an AE  could fall in either one of two g rades (i.e., the  severity of an AE could be  
either grade 2 or grade 3), sites should s elect the higher of the two grades. 
 
Laboratory Val ues 
General. An asymptom atic, abnormal laboratory finding  without an accompanying AE should  
not be  reported to DAIDS in an expedited tim eframe unless it m eets protocol-specific reporting 
requirements.  Sites should refer to the  applicable network standards for reporting abnormal 
laboratory findings on t he CRFs. 
 
Valu es below Grade  1.  Any laboratory value that is b etween the  ULN and grade 1 (for high 
values) or the LLN and grade 1 (for low v alues) should not be  graded or reported as an AE. 
Sites should consult the  Manual for E xpedited Reporting of Ad verse Events to DA IDS, Version  
2.0 and th eir protocol when making an assessment of the need to report an AE. 
 
Overlap of Local Laboratory  Normal Valu es with Grading Table Rang es.  When local laboratory 
normal values fall within  grading table laboratory ranges, the  severity grading is based on t he 
ranges in the  grading table unless there is a protocol-specific grading criterion for the laboratory
DAIDS AE Gradin g Table Version 2.0- Nov ember 2014 
Page 6 Instructions for Use    
  
value.  For example, â€œMagnesium,  Low" has a grade 1 range of 1.2 to <  1.4 mEq /L, while  a 
particular laboratoryâ€™s normal range for magnesium m ay be 1.3 to 2.8 mE q/L.  If a study 
participantâ€™s magnesium  laboratory value is 1.3 mEq /L, the laboratory value should be  graded as 
grade 1. 
 
  
Estimating Severity Grade for Parameters Not  Identified in the Grading Table 
The functional table below should be  used to g rade the severity of an AE t hat is not sp ecifically 
identified in the  grading table.  In addition, all deaths related to an AE  are to be  classified as 
grade 5. 
 
PARA METER  GRADE 1 
MILD GRADE 2 
MODERATE GRADE 3 
SEVERE GRADE 4 
POTENTIALLY LIFE-
THREATENING 
Clinical adverse 
event  NOT 
identified 
elsewhere in the 
grading table Mild symptoms 
causing no or 
minimal interference 
with usual social & 
functional activities 
with intervention not 
indicated Mod erate symptoms 
causing greater than 
minimal interference 
with usual social & 
functional activities 
with intervention 
indicated Severe symptoms 
causing inability to 
perform usual social & 
functional activities with 
intervention or 
hospitalization indicated Potentially life-threatening 
symptoms causing inability to 
perform basic self-care 
functions with intervention 
indicated to prevent 
permanent impairment, 
persistent disability, or death 
DAIDS AE Gradin g Table Version 2.0- Nov ember 2014 
Page 7 Major Clinical Conditions 
Cardiovascular  
    
PARA METER   
GRADE 1 
MILD  
GRADE 2 
MODERATE  
GRADE 3 
SEVERE  
GRADE 4 
POTENTIALLY 
LIFE- 
THREATENING 
Arrhythmia 
(by ECG or physical 
examination) 
Specify type, if applicable No symptoms AND 
No intervention 
indicated No symptoms AND 
Non-urgent 
intervention indicated Non-life-threatening 
symptoms  AND 
Non-urgent 
intervention indicated Life-threatening 
arrhythmia OR Urgent 
intervention indicated 
Blood Pressure 
Abnormalities 1 
Hypertension (with the 
lowest reading taken 
after repeat testing 
during a visit) 
â‰¥ 18 years of age  
 
 
140 to < 160 mmHg 
systolic 
OR 
90 to < 100 mmHg 
diastolic  
 
 
â‰¥ 160 to < 180 
mmHg systolic 
OR 
â‰¥ 100 to < 110 
mmHg diastolic  
 
 
â‰¥ 180 mmHg systolic 
OR 
â‰¥ 110 mmHg diastolic  
 
 
Life-threatening 
consequences in a 
participant not 
previously diagnosed 
with hypertension (e.g., 
malignant hypertension) 
OR Hospitalization 
indicated 
< 18 years of age > 120/80 mmHg â‰¥ 95th to < 99th 
percentile + 5  mmHg 
adjusted for age, 
height, and gender 
(systolic and/or 
diastolic) â‰¥ 99th percentile 
+ 5 mmHg adjusted 
for age, height, and 
gender (systolic 
and/or diastolic) Life-threatening 
consequences in a 
participant not 
previously diagnosed 
with hypertension (e.g., 
malignant hypertension) 
OR Hospitalization 
indicated 
Hypotension No symptoms Symptoms corrected 
with oral fluid 
replacement Symptoms AND IV 
fluids indicated Shock requiring use of 
vasopressors or 
mechanical assistance to 
maintain blood pressure 
Cardiac Ischemia or 
Infarction 
Report only one NA NA New symptoms with 
ischemia (stable 
angina) OR New 
testing consistent with 
ischemia Unstable angina OR 
Acute myocardial 
infarction 
Hear t Failure No symptoms AND 
Laboratory or 
cardiac imaging 
abnormalities Symptoms with mild 
to moderate activity 
or exertion Symptoms at rest or 
with minimal activity 
or exertion (e.g., 
hypoxemia) OR 
Intervention indicated 
(e.g., oxyge n) Life-threatening 
consequences OR Urgent 
intervention indicated 
(e.g., vasoactive 
medications, ventricular 
assist device, heart 
transplant) 
Hemorrhage 
(with significant acute 
blood loss) NA Symptoms AND  No 
transfusion indicated Symptoms AND 
Transfusion of â‰¤ 2 
units packed RBCs 
indicated Life-threatening 
hypotension OR 
Transfusion of > 2 units 
packed RBCs ( for 
children, packed RBCs  
> 10 cc/kg) indicated 
 
1 Blood pressure norms for children < 18 years of age can be foun d in: Expert Panel on Integrated Guidelines for Cardiovascular Health and 
Risk 
Reduction in Children and Adolescents. Pediatrics 2011;128;S213; originally pub lished online Nov ember 14, 2011; DOI: 10.1542/peds.2009- 
2107C.
DAIDS AE Gradin g Table Version 2.0- Nov ember 2014 
Page 8 Cardiovascular 
  
   
PARA METER   
GRADE 1 
MILD  
GRADE 2 
MODERATE  
GRADE 3 
SEVERE  
GRADE 4 
POTENTIALLY 
LIFE- 
THREATENING 
Prolonged PR Interval 
or AV Block 
Report only one 
> 16 years  of age PR interval 0.21 to < 
0.25 seconds PR interval â‰¥ 0.25 
seconds OR Type I 
2nd degree AV block Type II 2nd degree 
AV block OR 
Ventricular pause â‰¥ 
3.0 seconds Complete AV block 
â‰¤ 16 years of age 1st degree AV block 
(PR interval 
> normal for age and 
rate) Type I 2nd degree AV 
block Type II 2nd degree 
AV block OR 
Ventricular pause â‰¥ 
3.0 seconds Complete AV block 
Prolonged QTc 
Interval 2 0.45 to 0.47 seconds > 0.47 to 0.50 
seconds  > 0.50 seconds OR 
â‰¥ 0.06 seconds above 
baseline Life-threatening 
consequences (e.g., 
Torsade de pointes, other 
associated serious 
ventricular dysrhythmia) 
Thrombosis or 
Embolism 
Report only one NA Symptoms AND No 
intervention indicated Symptoms AND 
Intervention indicated Life-threatening embolic 
event (e.g., pulmonary 
embolism, thrombus) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 As per Bazettâ€™s formula.
Dermatologic 
3 For pruritus associated with injections or infusions, see the Site Reactions to Injections and Infusions section 
(page 23). 
DAIDS AE Gradin g Table Version 2.0- Nov ember 2014 
Page 9  
  
  
PARA METER   
GRADE 1 
MILD  
GRADE 2 
MODERATE  
GRADE 3 
SEVERE  
GRADE 4 
POTENTIALLY 
LIFE- 
THREATENING 
Alopecia (scalp only) Detectable by study 
participant, 
caregiver, or 
physician AND  
Causing no or 
minimal interference 
with usual social & 
functional activities Obvious on visual 
inspection AND 
Causing greater than 
minimal interference 
with usual social & 
functional activities NA NA 
Bruising Localized to one 
area Localized to more 
than one area Generalized NA 
Cellulitis NA Non-parenteral 
treatment indicated 
(e.g., oral antibiotics, 
antifungals, 
antivirals) IV treatment indicated 
(e.g., IV antibiotics, 
antifungals, antivirals) Life-threatening 
consequences (e.g., 
sepsis, tissue necrosis) 
Hyperpigmentation Slight or localized 
causing no or 
minimal interference 
with usual social & 
functional activities Marked or 
generalized causing 
greater than minimal 
interference with 
usual social & 
functional activities NA NA 
Hypopigmentation Slight or localized 
causing no or 
minimal interference 
with usual social & 
functional activities Marked or 
generalized causing 
greater than minimal 
interference with 
usual social & 
functional activities NA NA 
Petechiae Localized to one 
area Localized to more 
than one area Generalized NA 
Pruritus 3 
(without skin lesions) Itching causing no 
or minimal 
interference with 
usual social & 
functional activities Itching causing 
greater than minimal 
interference with 
usual social & 
functional activities Itching causing 
inability to perform 
usual social & 
functional activities NA 
Rash 
Specify type, if applicable Localized rash Diffuse rash OR 
Target lesions Diffuse rash AND 
Vesicles or limited 
number of bullae or 
superficial ulcerations 
of mucous membrane 
limited to one site  Extensive or generalized 
bullous lesions OR 
Ulceration of mucous 
membrane involving two 
or more distinct mucosal 
sites OR Stevens- 
Johnson syndrome OR 
Toxic epidermal 
necrolysis 
Endo crine and Metabolic 
DAIDS AE Gradin g Table Version 2.0- Nov ember 2014 
Page 10  
  
 
   
PARA METER   
GRADE 1 
MILD  
GRADE 2 
MODERATE  
GRADE 3 
SEVERE  
GRADE 4 
POTENTIALLY 
LIFE- 
THREATENING 
Diabetes Mellitus Controlled without 
medication Controlled with 
medication OR 
Mod ification of 
current medication 
regimen Uncontrolled despite 
treatment 
modification OR 
Hospitalization for 
imme diate glucose 
control indicated Life-threatening 
consequences (e.g., 
ketoacidosis, 
hyperosmolar non- 
ketotic coma, end organ 
failure) 
Gynecomastia Detectable by study 
participant, 
caregiver, or 
physician AND  
Causing no or 
minimal interference 
with usual social & 
functional activities Obvious on visual 
inspection AND 
Causing pain with 
greater than minimal 
interference with 
usual social & 
functional activities Disfiguring changes 
AND Symptoms 
requiring intervention 
or causing inability to 
perform usual social 
& functional activities NA 
Hyperthyroidism No symptoms AND 
Abnormal laboratory 
value Symptoms causing 
greater than minimal 
interference with 
usual social & 
functional activities 
OR Thyroid 
suppression therapy 
indicated Symptoms causing 
inability to perform 
usual social & 
functional activities 
OR Uncontrolled 
despite treatment 
modification Life-threatening 
consequences (e.g., 
thyroid storm) 
Hypothyroidism No symptoms AND 
Abnormal laboratory 
value Symptoms causing 
greater than minimal 
interference with 
usual social & 
functional activities 
OR  Thyroid 
replacement therapy 
indicated Symptoms causing 
inability to perform 
usual social & 
functional activities 
OR Uncontrolled 
despite treatment 
modification Life-threatening 
consequences (e.g., 
myxedema coma) 
Lipoatrophy 4 Detectable by study 
participant, 
caregiver, or 
physician AND  
Causing no or 
minimal interference 
with usual social & 
functional activities Obvious on visual 
inspection AND 
Causing greater than 
minimal interference 
with usual social & 
functional activities Disfiguring changes NA 
Lipohypertrophy 5 Detectable by study 
participant, 
caregiver, or 
physician AND  
Causing no or 
minimal interference 
with usual social & 
functional activities Obvious on visual 
inspection AND 
Causing greater than 
minimal interference 
with usual social & 
functional activities Disfiguring changes NA 
 
4 Definition: A disorder characterized by fat loss in the face, extremities, and buttocks. 
5 Definition: A disorder characterized by abnormal fat accumulation on the back of the neck, breasts, and abdomen.
DAIDS AE Gradin g Table Version 2.0- Nov ember 2014 
Page 11 Gastrointestinal  
    
PARA METER   
GRADE 1 
MILD  
GRADE 2 
MODERATE  
GRADE 3 
SEVERE  
GRADE 4 
POTENTIALLY 
LIFE- 
THREATENING 
Anorexia Loss of appetite 
without decreased 
oral intake Loss of appetite 
associated with 
decreased oral intake 
without significant 
weight loss Loss of appetite 
associated with 
significant weight loss Life-threatening 
consequences OR 
Aggressive intervention 
indicated (e.g., tube 
feeding, total parenteral 
nutrition) 
Ascites No symptoms Symptoms AND 
Intervention indicated 
(e.g., diuretics, 
therapeutic 
paracentesis) Symptoms recur or 
persist despite 
intervention Life-threatening 
consequences 
Bloating or Dist ension 
Report only one Symptoms causing 
no or minimal 
interference with 
usual social & 
functional activities Symptoms causing 
greater than minimal 
interference with 
usual social & 
functional activities Symptoms causing 
inability to perform 
usual social & 
functional activities NA 
Cholecystitis  NA Symptoms AND 
Medical intervention 
indicated Radiologic, 
endoscopic, or 
operative intervention 
indicated Life-threatening 
consequences (e.g., 
sepsis, perforation) 
Constipation NA Persistent 
constipation requiring 
regular use of dietary 
modifications, 
laxatives, or enemas Obstipation with 
manual evacuation 
indicated Life-threatening 
consequences (e.g., 
obstruction) 
Diarrhea 
â‰¥ 1 year of age  
Transient or 
intermittent episodes 
of unformed stools 
OR Increase of â‰¤ 3 
stools over baseline 
per 24-hour period  
Persistent episodes of 
unformed to watery 
stools OR Increase of 
4 to  6 stools over 
baseline per 24-hour 
period  
Increase of â‰¥ 7 stools 
per 24-hour period 
OR IV fluid 
replacement indicated  
Life-threatening 
consequences (e.g., 
hypotensive shock) 
Dysphagia or 
Odynophagia 
Report only one and 
specify location Symptoms but able 
to eat usual diet Symptoms causing 
altered dietary intake 
with no intervention 
indicated Symptoms causing 
severely altered 
dietary intake with 
intervention indicated Life-threatening 
reduction in oral intake 
Gastrointestinal 
Bleeding Not requiring 
intervention other 
than iron 
supplement Endoscopic 
intervention indicated Transfusion indicated Life-threatening 
consequences (e.g., 
hypotensive shock) 
DAIDS AE Gradin g Table Version 2.0- Nov ember 2014 
Page 12 Gastrointestinal  
   
PARA METER   
GRADE 1 
MILD  
GRADE 2 
MODERATE  
GRADE 3 
SEVERE  
GRADE 4 
POTENTIALLY 
LIFE- 
THREATENING 
Mucositis or Stomatitis 
Report only one and 
specify location Mucosal erythema Patchy 
pseudomembranes or 
ulcerations Confluent 
pseudomembranes or 
ulcerations OR 
Mucosal bleeding 
with minor trauma Life-threatening 
consequences (e.g., 
aspiration, choking) OR 
Tissue necrosis OR 
Diffuse spontaneous 
mucosal bleeding 
Nausea Transient (< 24 
hours) or 
intermittent AND 
No or minimal 
interference with 
oral intake Persistent nausea 
resulting in decreased 
oral intake for 24 to 
48 hours Persistent nausea 
resulting in minimal 
oral intake for > 48 
hours OR 
Rehydration indicated 
(e.g., IV fluids) Life-threatening 
consequences (e.g., 
hypotensive shock) 
Pancreatitis NA Symptoms with 
hospitalization not 
indicated Symptoms 
with 
hospitalizati
on indicated  Life-threatening 
consequences (e.g., 
circulatory failure, 
hemorrhage, sepsis) 
Perforation 
(colon or rectum) NA NA Intervention indicated Life-threatening 
consequences 
Proctitis Rectal discomfort 
with no intervention 
indicated Symptoms causing 
greater than minimal 
interference with 
usual social & 
functional activities 
OR Medical 
intervention indicated Symptoms causing 
inability to perform 
usual social & 
functional activities 
OR Operative 
intervention indicated Life-threatening 
consequences (e.g., 
perforation) 
Rectal Discharge Visible discharge Discharge requiring 
the use of pads NA NA 
Vomiting Transient or 
intermittent AND 
No or minimal 
interference with 
oral intake Frequent episodes 
with no or mild 
dehydration Persistent vomiting 
resulting in orthostatic 
hypotension OR 
Aggressive 
rehydration indicated 
(e.g., IV fluids) Life-threatening 
consequences (e.g., 
hypotensive shock) 
DAIDS AE Gradin g Table Version 2.0- Nov ember 2014 
Page 13 Musculoskeletal   
  
  
PARA METER   
GRADE 1 
MILD  
GRADE 2 
MODERATE  
GRADE 3 
SEVERE  
GRADE 4 
POTENTIALLY 
LIFE- 
THREATENING 
Arthralgia Joint pain causing 
no or minimal 
interference with 
usual social & 
functional activities Joint pain causing 
greater than minimal 
interference with 
usual social & 
functional activities Joint pain causing 
inability to perform 
usual social & 
functional activities Disabling joint pain 
causing inability to 
perform basic self-care 
functions 
Arthritis Stiffness or joint 
swelling causing no 
or minimal 
interference with 
usual social & 
functional activities Stiffness or joint 
swelling causing 
greater than minimal 
interference with 
usual social & 
functional activities Stiffness or joint 
swelling causing 
inability to perform 
usual social & 
functional activities Disabling joint stiffness 
or swelling causing 
inability to perform basic 
self-care functions 
Myalgia (generalized) Muscle pain causing 
no or minimal 
interference with 
usual social & 
functional activities Muscle pain causing 
greater than minimal 
interference with 
usual social & 
functional activities Muscle pain causing 
inability to perform 
usual social & 
functional activities Disabling muscle pain 
causing inability to 
perform basic self-care 
functions 
Osteonecrosis NA No symptoms but 
with radiographic 
findings AND No 
operative intervention 
indicated Bone pain with 
radiographic findings 
OR Operative 
intervention indicated Disabling bone pain with 
radiographic findings 
causing inability to 
perform basic self-care 
functions 
Osteopenia 6 
â‰¥ 30 years of age  
BMD t-score 
-2.5 to -1  
NA  
NA  
NA 
< 30 years of age BMD z-score 
-2 to -1 NA NA NA 
Osteoporosis6 
â‰¥ 30 years of age  
NA  
BMD t-score < -2.5  
Pathologic fracture 
(e.g., compression 
fracture causing loss 
of vertebral height)  
Pathologic fracture 
causing life-threatening 
consequences 
< 30 years of age NA BMD z-score < -2 Pathologic fracture 
(e.g., compression 
fracture causing loss 
of vertebral height) Pathologic fracture 
causing life-threatening 
consequences 
  
 
 
 
 
 
 
 
 
 
6 BMD t and z scores can be found in: Kanis JA on behalf of the World Health Organization Scientific Group (2007). Assessment of osteoporosis 
at the primary health-care level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of 
Sheffield, UK. 2007: Printed by the University of Sheffield.
DAIDS AE Gradin g Table Version 2.0- Nov ember 2014 
Page 14 Neurologic  
    
PARA METER   
GRADE 1 
MILD  
GRADE 2 
MODERATE  
GRADE 3 
SEVERE  
GRADE 4 
POTENTIALLY 
LIFE- 
THREATENING 
Acute CNS Ischemia NA NA Transient ischemic 
attack Cerebral vascular 
accident (e.g., stroke 
with neurological 
deficit) 
Altered Mental Status 
(for Dementia, see 
Cognitive, Behavioral, or 
Attentional Disturbance 
below) Changes causing no 
or minimal 
interference with 
usual social & 
functional activities Mild lethargy or 
somnolence causing 
greater than minimal 
interference with 
usual social & 
functional activities Confusion, memory 
impairment, lethargy, 
or  somnolence 
causing inability to 
perform usual social 
& functional activities Delirium OR 
Obtundation OR 
Coma 
Ataxia Symptoms causing 
no or minimal 
interference with 
usual social & 
functional activities 
OR No symptoms 
with ataxia detected 
on examination Symptoms causing 
greater than minimal 
interference with 
usual social & 
functional activities Symptoms causing 
inability to perform 
usual social & 
functional activities Disabling symptoms 
causing inability to 
perform basic self-care 
functions 
Cognitive, Behavioral, 
or Att entional 
Disturbance (includes 
dementia and attention 
deficit disorder) 
Specify type, if applicable Disability causing 
no or minimal 
interference with 
usual social & 
functional activities 
OR Specialized 
resources not 
indicated Disability causing 
greater than minimal 
interference with 
usual social & 
functional activities 
OR Specialized 
resources on part- 
time basis indicated Disability causing 
inability to perform 
usual social & 
functional activities 
OR Specialized 
resources on a full- 
time basis indicated Disability causing 
inability to perform 
basic self-care functions 
OR Institutionalization 
indicated 
Developmental Delay 
< 18 years of age 
  
Specify type, if applicable Mild developmental 
delay, either motor 
or cognitive, as 
determined by 
comparison with a 
developmental 
screening tool 
appropriate for the 
setting Mod erate 
developmental delay, 
either motor or 
cognitive, as 
determined by 
comparison with a 
developmental 
screening tool 
appropriate for the 
setting Severe developmental 
delay, either motor or 
cognitive, as 
determined by 
comparison with a 
developmental 
screening tool 
appropriate for the 
setting Developmental 
regression, either motor 
or cognitive, as 
determined by 
comparison with a 
developmental screening 
tool appropriate for the 
setting 
Headache Symptoms causing 
no or minimal 
interference with 
usual social & 
functional activities Symptoms causing 
greater than minimal 
interference with 
usual social & 
functional activities Symptoms causing 
inability to perform 
usual social & 
functional activities Symptoms causing 
inability to perform 
basic self-care functions 
OR Hospitalization 
indicated  OR Headache 
with significant 
impairment of alertness 
or other neurologic 
function 
DAIDS AE Gradin g Table Version 2.0- Nov ember 2014 
Page 15 Neurologic  
   
PARA METER   
GRADE 1 
MILD  
GRADE 2 
MODERATE  
GRADE 3 
SEVERE  
GRADE 4 
POTENTIALLY 
LIFE- 
THREATENING 
Neuromuscular 
Weakness (includes 
myopathy and 
neuropathy) 
Specify type, if applicable Minimal muscle 
weakness causing no 
or minimal 
interference with 
usual social & 
functional activities 
OR No symptoms 
with decreased 
strength on 
examination Muscle weakness 
causing greater than 
minimal interference 
with usual social & 
functional activities Muscle weakness 
causing inability to 
perform usual social 
& functional activities Disabling muscle 
weakness causing 
inability to perform 
basic self-care functions 
OR  Respiratory muscle 
weakness impairing 
ventilation 
Neurosensory Alteration 
(includes paresthesia and 
painful neuropathy) 
Specify type, if applicable Minimal paresthesia 
causing no or 
minimal 
interference with 
usual social & 
functional activities 
OR No symptoms 
with sensory 
alteration on 
examination Sensory alteration or 
paresthesia causing 
greater than minimal 
interference with 
usual social & 
functional activities Sensory alteration or 
paresthesia causing 
inability to perform 
usual social & 
functional activities Disabling sensory 
alteration or paresthesia 
causing inability to 
perform basic self-care 
functions 
Seizures 
New Onset Seizure 
â‰¥ 18 years of age  
NA  
NA  
1 to  3 seizures  
Prolonged and repetitive 
seizures (e.g., status 
epilepticus) OR Difficult 
to control (e.g., 
refractory epilepsy) 
Pre-existing Seizure NA Increased frequency 
from previous level 
of control without 
change in seizure 
character Change in seizure 
character either in 
duration or quality 
(e.g., severity or 
focality) Prolonged and repetitive 
seizures (e.g., status 
epilepticus) OR Difficult 
to control (e.g., 
refractory epilepsy) 
Syncope Near syncope 
without loss of 
consciousness (e.g., 
pre-syncope) Loss of consciousness 
with no intervention 
indicated Loss of consciousness 
AND Hospitalization 
or intervention 
required NA 
DAIDS AE Gradin g Table Version 2.0- Nov ember 2014 
Page 16 Pregnancy, Puerperium, and Perinatal   
  
  
PARA METER   
GRADE 1 
MILD  
GRADE 2 
MODERATE  
GRADE 3 
SEVERE  
GRADE 4 
POTENTIALLY 
LIFE- 
THREATENING 
Fetal Death or Stillbirth 
(report using motherâ€™s 
participant ID) 
Report only one NA NA Fetal loss occurring at 
â‰¥ 20 weeks gestation NA 
Preterm Delivery 7 
(report using motherâ€™s 
participant ID) Delivery at 34 to 
< 37 weeks 
gestational age Delivery at 28 to 
< 34 weeks 
gestational age Delivery at 24 to 
< 28 weeks 
gestational age Delivery at < 24 weeks 
gestational age 
Spontaneous Abortion 
or Miscarriage 8 (report 
using motherâ€™s participant 
ID) 
Report only one Chemical pregnancy Uncomplicated 
spontaneous abortion 
or miscarriage Complicated 
spontaneous abortion 
or miscarriage NA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 Definition:  A delivery of a live-born neonate occurring at â‰¥ 20 to < 37 weeks gestational age. 
8 Definition:  A clinically recognized pregnanc y occurring at < 20 weeks gestational age.
DAIDS AE Gradin g Table Version 2.0- Nov ember 2014 
Page 17 Psychiatric  
    
PARA METER   
GRADE 1 
MILD  
GRADE 2 
MODERATE  
GRADE 3 
SEVERE  
GRADE 4 
POTENTIALLY 
LIFE- 
THREATENING 
Insomnia Mild difficulty 
falling asleep, 
staying asleep, or 
waking up early Mod erate difficulty 
falling asleep, staying 
asleep, or waking up 
early Severe difficulty 
falling asleep, staying 
asleep, or waking up 
early NA 
Psychiatric Di sorders 
(includes anxiety, 
depression, mania, and 
psychosis) 
Specify disorder Symptoms with 
intervention not 
indicated OR 
Behavior causing no 
or minimal 
interference with 
usual social & 
functional activities Symptoms with 
intervention indicated 
OR Behavior causing 
greater than minimal 
interference with 
usual social & 
functional activities Symptoms with 
hospitalization 
indicated OR 
Behavior causing 
inability to perform 
usual social & 
functional activities Threatens harm to self or 
others OR Acute 
psychosis OR Behavior 
causing inability to 
perform basic self-care 
functions 
Suicidal Ideation or 
Attempt 
Report only one Preoccupied with 
thoughts of death 
AND No wish to kill 
oneself Preoccupied with 
thoughts of death 
AND Wish to kill 
oneself with no 
specific plan or intent Thoughts of killing 
oneself with partial or 
complete plans but no 
attempt to do so OR 
Hospitalization 
indicated Suicide attempted 
DAIDS AE Gradin g Table Version 2.0- Nov ember 2014 
Page 18 Respiratory  
    
PARA METER   
GRADE 1 
MILD  
GRADE 2 
MODERATE  
GRADE 3 
SEVERE  
GRADE 4 
POTENTIALLY 
LIFE- 
THREATENING 
Acute Bronchospasm Forced expiratory 
volume in 1 second 
or peak flow 
reduced to 
â‰¥ 70 to < 80% OR 
Mild symptoms with 
intervention not 
indicated Forced expiratory 
volume in 1 second or 
peak flow 50 to 
< 70% OR Symptoms 
with intervention 
indicated OR 
Symptoms causing 
greater than minimal 
interference with 
usual social & 
functional activities Forced expiratory 
volume in 1 second 
or peak flow 25 to 
< 50% OR Symptoms 
causing inability to 
perform usual social 
& functional 
activities Forced expiratory 
volume in 1 second or 
peak flow < 25% OR 
Life-threatening 
respiratory or 
hemodynamic 
compromise OR 
Intubation 
Dyspnea or Respiratory 
Distress 
Report only one Dyspnea on exertion 
with no or minimal 
interference with 
usual social & 
functional activities 
OR Wheezing OR 
Minimal increase in 
respiratory rate for 
age Dyspnea on exertion 
causing greater than 
minimal interference 
with usual social & 
functional activities 
OR Nasal flaring OR 
Intercostal retractions 
OR Pulse oximetry 90 
to < 95% Dyspnea at rest 
causing inability to 
perform usual social 
& functional 
activities OR Pulse 
oximetry < 90% Respiratory failure with 
ventilator support 
indicated (e.g., CPAP, 
BPAP, intubation) 
DAIDS AE Gradin g Table Version 2.0- Nov ember 2014 
Page 19 Sensory  
    
PARA METER   
GRADE 1 
MILD  
GRADE 2 
MODERATE  
GRADE 3 
SEVERE  
GRADE 4 
POTENTIALLY 
LIFE- 
THREATENING 
Hear ing Loss 
â‰¥ 12 years of age  
NA  
Hearing aid or 
intervention not 
indicated  
Hearing aid or 
intervention indicated  
Profound bilateral 
hearing loss (> 80 dB at 
2 kHz and above) OR 
Non-serviceable hearing 
(i.e., >50 dB audiogram 
and <50% speech 
discrimination) 
Tinnitus Symptoms causing 
no or minimal 
interference with 
usual social & 
functional activities 
with intervention not 
indicated Symptoms causing 
greater than minimal 
interference with 
usual social & 
functional activities 
with intervention 
indicated Symptoms causing 
inability to perform 
usual social & 
functional activities NA 
Uveitis No symptoms AND 
Detectable on 
examination Anterior uveitis with 
symptoms OR 
Medicamy lasal 
intervention indicated Posterior or pan- 
uveitis OR Operative 
intervention indicated Disabling visual loss in 
affected eye(s) 
Vertigo Vertigo causing no 
or minimal 
interference with 
usual social & 
functional activities Vertigo causing 
greater than minimal 
interference with 
usual social & 
functional activities Vertigo causing 
inability to perform 
usual social & 
functional activities Disabling vertigo 
causing inability to 
perform basic self-care 
functions 
Visual Changes 
(assessed from baseline) Visual changes 
causing no or 
minimal interference 
with usual social & 
functional activities Visual changes 
causing greater than 
minimal interference 
with usual social & 
functional activities Visual changes 
causing inability to 
perform usual social 
& functional activities Disabling visual loss in 
affected eye(s) 
Systemic 
DAIDS AE Gradin g Table Version 2.0- Nov ember 2014 
Page 
2020  
    
PARA METER   
GRADE 1 
MILD  
GRADE 2 
MODERATE  
GRADE 3 
SEVERE  
GRADE 4 
POTENTIALLY 
LIFE- 
THREATENING 
Acute All ergic 
Reaction Localized urticaria 
(wheals) with no 
medical intervention 
indicated Localized urticaria 
with intervention 
indicated OR Mild 
angioedema with no 
intervention 
indicated Generalized urticaria 
OR Angioedema with 
intervention indicated 
OR Symptoms of mild 
bronchospasm Acute anaphylaxis OR 
Life-threatening 
bronchospasm OR 
Laryngeal edema 
Chills Symptoms causing no 
or minimal 
interference with usual 
social & functional 
activities Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Symptoms causing 
inability to perform 
usual social & 
functional activities NA 
Cytokine Release 
Syndrome9 Mild signs and 
symptoms AND 
Therapy (i.e., antibody 
infusion) interruption 
not indicated Therapy (i.e., 
antibody infusion) 
interruption 
indicated AND 
Respond s promptly 
to symptomatic 
treatment OR 
Prophylactic 
medications 
indicated for â‰¤ 24 
hours Prolonged severe signs 
and symptoms OR 
Recurrence of 
symptoms following 
initial improvement Life-threatening 
consequences (e.g., 
requiring pressor or 
ventilator support) 
Fatigue or Malaise 
Report only one Symptoms causing no 
or minimal 
interference with usual 
social & functional 
activities Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Symptoms causing 
inability to perform 
usual social & 
functional activities Incapacitating symptoms 
of fatigue or malaise 
causing inability to 
perform basic self-care 
functions 
Fever (non-axillary 
temperatures only) 38.0 to < 38.6Â°C or 
100.4 to < 101.5Â°F â‰¥ 38.6  to < 39.3Â°C 
or â‰¥ 101.5 to 
< 102.7Â°F â‰¥ 39.3 to < 40.0Â°C or 
â‰¥ 102.7 to < 104.0Â°F â‰¥ 40.0Â°C or â‰¥ 104.0Â°F 
Pain10 (not associated 
with study agent 
injections and not 
specified elsewhere) 
Specify location Pain causing no or 
minimal interference 
with usual social & 
functional activities Pain causing greater 
than minimal 
interference with 
usual social & 
functional activities Pain causing inability 
to perform usual social 
& functional activities Disabling pain causing 
inability to perform basic 
self-care functions OR 
Hospitalization indicated 
Serum Sickness 11 Mild signs and 
symptoms Mod erate signs and 
symptoms AND 
Intervention 
indicated (e.g., 
antihistamines) Severe signs and 
symptoms AND 
Higher level 
intervention indicated 
(e.g., steroids or IV 
fluids) Life-threatening 
consequences (e.g., 
requiring pressor or 
ventilator support) 
 
9 Definition: A disorder characterized by nausea, headache, tachycardia, hypotension, rash, and/or shortness of breath. 
10 For pain associated with injections or infusions, see the Site Reactions to Injections and Infusions section (page 23). 
11 Definition: A disorder characterized by fever, arthralgia, myalgia, skin eruptions, lymphad enopathy, marked discomfort, and/or dyspnea.
DAIDS AE Gradin g Table Version 2.0- Nov ember 2014 
Page 21  
    
PARA METER   
GRADE 1 
MILD  
GRADE 2 
MODERATE  
GRADE 3 
SEVERE  
GRADE 4 
POTENTIALLY 
LIFE- 
THREATENING 
Underweight12 
> 5 to 19 years of 
age  
NA  
WHO B MI z-score 
< -2 to â‰¤ -3  
WHO B MI z-score 
< -3  
WHO B MI z-score 
< -3 with life-threatening 
consequences 
Weight Loss (excludes 
postpartum weight 
loss) NA 5 to < 9% loss in 
body weight from 
baseline â‰¥ 9 to < 20% loss in 
body weight from 
baseline â‰¥ 20% loss in body weight 
from baseline OR 
Aggressive intervention 
indicated (e.g., tube 
feeding, total parenteral 
nutrition) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12 WHO reference tables may be accesed by clicking the desired age range or by accessing the following URLs: 
http://www.who.int/growthref/who2007_bmi_for_age/en/ for participants > 5 to 19 years of age and 
http://www.who.int/childgrowth/standards/chart_catalogue/en/ for those â‰¤ 5 years of age.
Urinary 
DAIDS AE Gradin g Table Version 2.0- Nov ember 2014 
Page 
2222  
 22    
PARA METER   
GRADE 1 
MILD  
GRADE 2 
MODERATE  
GRADE 3 
SEVERE  
GRADE 4 
POTENTIALLY 
LIFE- 
THREATENING 
Urinary Tract 
Obstruction NA Signs or symptoms of 
urinary tract 
obstruction without 
hydronephrosis or 
renal dysfunction Signs or symptoms of 
urinary tract 
obstruction with 
hydronephrosis or 
renal dysfunction Obstruction causing life- 
threatening 
consequences 
 
  
Site Reac tions to Injectio ns and Infusions 
  
PARA METER   
GRADE 1 
MILD  
GRADE 2 
MODERATE  
GRADE 3 
SEVERE  
GRADE 4 
POTENTIALLY 
LIFE- 
THREATENING 
Injection Site P ain or 
Tenderness 
Report only one Pain or tenderness 
causing no or 
minimal limitation 
of use of limb Pain or tenderness 
causing greater than 
minimal limitation of 
use of limb Pain or tenderness 
causing inability to 
perform usual social 
& functional activities Pain or tenderness 
causing inability to 
perform basic self-care 
function OR 
Hospitalization indicated 
Injection Site E rythema 
or Redness 13 
Report only one 
> 15 years of age  
 
 
2.5 to < 5 cm in 
diameter OR 6.25 to 
< 25 cm2 surface 
area AND 
Symptoms causing 
no or minimal 
interference with 
usual social & 
functional activities  
 
 
â‰¥ 5 to < 10 cm in 
diameter OR â‰¥ 25 to 
< 100 cm2 surface 
area OR  Symptoms 
causing greater than 
minimal interference 
with usual social & 
functional activities  
 
 
â‰¥ 10 cm in diameter 
OR â‰¥ 100 cm2 surface 
area OR Ulceration 
OR Secondary 
infection OR Phlebitis 
OR Sterile abscess 
OR Drainage OR 
Symptoms causing 
inability to perform 
usual social & 
functional activities  
 
 
Potentially life- 
threatening 
consequences (e.g., 
abscess, exfoliative 
dermatitis, necrosis 
involving dermis or 
deeper tissue) 
Injection Site 
Induration or Swelling 
Report only one 
> 15 years of age Same as for 
Injection Site 
Erythema or 
Redness, > 15 years 
of age Same as for Injection 
Site E rythema or 
Redness, > 15 years 
of age Same as for Injection 
Site E rythema or 
Redness, > 15 years 
of age Same as for Injection 
Site E rythema or 
Redness, > 15 years of 
age 
Injection Site P ruritus Itching localized to 
the injection site that 
is relieved 
spontaneously or in 
< 48 hours of 
treatment Itching beyond the 
injection site that is 
not generalized OR 
Itching localized to 
the injection site 
requiring â‰¥ 48 hours 
treatment Generalized itching 
causing inability to 
perform usual social 
& functional activities NA 
 
 
 
13 Injection Site Erythema or Redness should be evaluated and graded using the greatest single diameter or measured surface area.
Laboratory Values 
Chemistries 
14 Direct bilirubin > 1.5 mg/dL in a participant < 28 days of age should be graded as grade 2, if < 10% of the total 
bilirubin. 
DAIDS AE Gradin g Table Version 2.0- Nov ember 2014 
Page 
2424  
    
PARA METER   
GRADE 1 
MILD  
GRADE 2 
MODERATE  
GRADE 3 
SEVERE  
GRADE 4 
POTENTIALLY 
LIFE- 
THREATENING 
Acidosis NA pH â‰¥ 7.3 to < LLN  pH < 7.3 without life- 
threatening 
consequences pH < 7.3 with life- 
threatening 
consequences 
Albumin, Low 
(g/dL; g/L) 3.0 to < LLN  
30  to < LLN â‰¥ 2.0 to < 3.0 
â‰¥ 20  to < 30 < 2.0 
< 20 NA 
Alkaline Phosphatase, 
High 1.25  to < 2.5 
x ULN 2.5  to < 5.0 x ULN 5.0 to < 10.0 x ULN â‰¥ 10.0 x ULN 
Alkalosis NA pH > U LN to â‰¤ 7.5 pH > 7.5 without life- 
threatening 
consequences pH > 7.5 with life- 
threatening 
consequences 
ALT or SGPT, High 
Report only one 1.25  to < 2.5 
x ULN 2.5 to < 5.0 x ULN 5.0  to < 10.0 x ULN â‰¥ 10.0 x ULN 
Amylase (P ancreatic) or 
Amylase (T otal), High 
Report only one 1.1  to < 1.5 x ULN 1.5  to < 3.0 x ULN 3.0  to < 5.0 x ULN â‰¥ 5.0 x ULN 
AST or SGOT, High 
Report only one 1.25  to < 2.5 
x ULN 2.5  to < 5.0 x ULN 5.0  to < 10.0 x ULN â‰¥ 10.0 x ULN 
Bicarbonate, Low 
(mEq/L; mmol/L) 16.0 to <  LLN  
16.0 to <  LLN 11.0  to < 16.0 
11.0  to < 16.0 8.0  to < 11.0 
8.0  to < 11.0 < 8.0 
< 8.0 
Bilirubin 
Direct Bilir ubin14, 
High 
> 28 days of age   
 
NA   
 
NA   
 
> ULN   
 
> ULN with life- 
threatening 
consequences (e.g., signs 
and symptoms of liver 
failure) 
â‰¤ 28 days of age ULN to â‰¤ 1 mg/dL > 1 to â‰¤ 1.5 mg/dL > 1.5 to â‰¤ 2 mg/dL > 2 mg/dL 
Total Bilir ubin, High 
> 28 days of age  
1.1 to < 1.6 x ULN  
1.6 to < 2.6 x ULN  
2.6 to < 5.0 x ULN  
â‰¥  5.0 x ULN 
â‰¤ 28 days of age See Appendix A. 
Total Bilirubin for 
Term and Preterm 
Neonates See Appendix A. 
Total Bilirubin for 
Term and Preterm 
Neonates See Appendix A. 
Total Bilirubin for 
Term and Preterm 
Neonates See Appendix A. Total 
Bilirubin for Term and 
Preterm Neonates 
Calcium, High 
(mg/dL; mmol/L) 
 
â‰¥ 7 days of age  
 
10.6   to < 11.5 
2.65  to < 2.88  
 
11.5  to < 12.5 
2.88  to < 3.13  
 
12.5   to < 13.5 
3.13  to < 3.38  
 
â‰¥  13.5 
â‰¥  3.38 
< 7 days of age 11.5  to < 12.4 
2.88  to < 3.10 12.4  to < 12.9 
3.10  to < 3.23 12.9  to < 13.5 
3.23  to < 3.38 â‰¥  13.5 
â‰¥  3.38 
Chemistries 
15 Use the applicable formula (i.e., Cockroft-Gault in mL/min or Schwatrz in 
mL/min/1.73m2). 
DAIDS AE Gradin g Table Version 2.0- Nov ember 2014 
Page 25  
    
PARA METER   
GRADE 1 
MILD  
GRADE 2 
MODERATE  
GRADE 3 
SEVERE  
GRADE 4 
POTENTIALLY 
LIFE- 
THREATENING 
Calcium (Ionized), High 
(mg/dL; mmol/L) > ULN to < 6.0 
> ULN  to < 1.5 6.0 to < 6.4 
1.5 to < 1.6 6.4 to < 7.2 
1.6 to < 1.8 â‰¥ 7.2 
â‰¥ 1.8 
Calcium, Low 
(mg/dL; mmol/L) 
 
â‰¥ 7 days of age  
 
7.8  to < 8.4 
1.95  to < 2.10  
 
7.0   to < 7.8 
1.75  to < 1.95  
 
6.1  to < 7.0 
1.53  to < 1.75  
 
< 6.1 
< 1.53 
< 7 days of age 6.5  to < 7.5 
1.63  to < 1.88 6.0 to < 6.5 
1.50  to < 1.63 5.50  to < 6.0 
1.38  to < 1.50 < 5.50 
< 1.38 
Calcium (Ionized),  Low 
(mg/dL; mmol/L) < LLN  to 4.0 
< LLN to 1.0 3.6 to < 4.0 
0.9 to < 1.0 3.2 to < 3.6 
0.8 to < 0.9 < 3.2 
< 0.8 
Cardiac Troponin I, 
High NA NA NA Levels consistent with 
myocardial infarction or 
unstable angina as 
defined by the local 
laboratory 
Creatine Kinase, High 3 to < 6 x ULN 6 to < 10 x ULN 10 to < 20 x ULN â‰¥ 20 x ULN 
Creatinine, High 1.1 to 1.3 x ULN > 1.3 to 1.8 x ULN 
OR Increase of 
> 0.3 mg/dL above 
baseline > 1.8  to < 3.5 
x ULN OR Increase 
of 1.5 to < 2.0 x 
above baseline â‰¥ 3.5 x ULN OR 
Increase of â‰¥ 2.0 x 
above baseline 
Creatinine Clearance 15 
or eGFR, Low 
Report only one NA < 90 to 60 ml/min or 
ml/min/1.73 m2 
OR 
10 to < 30% decrease 
from baseline < 60 to 30 ml/min or 
ml/min/1.73 m2 
OR 
â‰¥ 30 to < 50% 
decrease from 
baseline < 30 ml/min or 
ml/min/1.73 m2 
OR 
â‰¥ 50% decrease from 
baseline or dialysis 
needed 
Glucose 
(mg/dL; mmol/L) 
 
Fasting, High  
 
110 to 125 
6.11 to < 6.95  
 
> 125 to 250 
6.95 to < 13.89  
 
> 250 to 500 
13.89 to < 27.75  
 
> 500 
â‰¥ 27.75 
Nonfasting, High 116 to 160 
6.44 to < 8.89 > 160 to 250 
8.89 to < 13.89 > 250 to 500 
13.89  to < 27.75 > 500 
â‰¥ 27.75 
Glucose, Low 
(mg/dL; mmol/L) 
 
â‰¥ 1 month of age  
 
55  to 64 
3.05  to 3.55  
 
40  to < 55 
2.22  to < 3.05  
 
30  to < 40 
1.67 to < 2.22  
 
< 30 
< 1.67 
< 1 month of age 50 to 54 
2.78  to 3.00 40 to < 50 
2.22 to < 2.78 30 to < 40 
1.67 to < 2.22 < 30 
< 1.67 
Lactate, High ULN to  < 2.0 
x ULN without 
acidosis â‰¥ 2.0 x ULN without 
acidosis Increased lactate with 
pH < 7.3 without life- 
threatening 
consequences Increased lactate with 
pH < 7.3 with life- 
threatening 
consequences 
DAIDS AE Gradin g Table Version 2.0- Nov ember 2014 
Page 26  
    
PARA METER   
GRADE 1 
MILD  
GRADE 2 
MODERATE  
GRADE 3 
SEVERE  
GRADE 4 
POTENTIALLY 
LIFE- 
THREATENING 
Lipase, High 1.1  to < 1.5 x ULN 1.5  to < 3.0 x ULN 3.0  to < 5.0 x ULN â‰¥ 5.0 x ULN 
Lipid Disorders 
(mg/dL; mmol/L) 
 
Cholesterol, Fasting, 
High 
â‰¥ 18 years of age   
 
 
 
200  to < 240 
5.18  to < 6.19   
 
 
 
240  to < 300 
6.19  to < 7.77   
 
 
 
â‰¥  300 
â‰¥  7.77   
 
 
 
NA 
< 18 years of age 170  to < 200 
4.40  to < 5.15 200  to < 300 
5.15  to < 7.77 â‰¥  300 
â‰¥  7.77 NA 
LDL,  Fasting, High 
â‰¥ 18 years of age  
130  to < 160 
3.37  to < 4.12  
160 to < 190 
4.12  to < 4.90  
â‰¥ 190 
â‰¥ 4.90  
NA 
> 2 to < 18 years of 
age 110  to < 130 
2.85  to < 3.34 130 to < 190 
3.34  to < 4.90 â‰¥ 190 
â‰¥ 4.90 NA 
Triglycerides, Fasting, 
High 150 to 300 
1.71 to 3.42 >300  to 500 
>3.42 to 5.7 >500 to < 1,000 
>5.7 to 11.4 > 1,000 
> 11.4 
Magnesium16, Low 
(mEq/L; mmol/L) 1.2   to < 1.4 
0.60  to < 0.70 0.9  to < 1.2 
0.45  to < 0.60 0.6  to < 0.9 
0.30  to < 0.45 < 0.6 
< 0.30 
Phosphate, Low 
(mg/dL; mmol/L) 
 
> 14 years of age  
 
2.0 to < LLN 
0.81 to < LLN  
 
1.4 to < 2.0 
0.65 to < 0.81  
 
1.0 to < 1.4 
0.32 to < 0.65  
 
< 1.0 
< 0.32 
1 to 14 years of age 3.0  to < 3.5 
0.97  to < 1.13 2.5  to < 3.0 
0.81  to < 0.97 1.5  to < 2.5 
0.48  to < 0.81 < 1.5 
< 0.48 
< 1 year of age 3.5  to < 4.5 
1.13  to < 1.45 2.5  to < 3.5 
0.81  to < 1.13 1.5  to < 2.5 
0.48  to < 0.81 < 1.5 
< 0.48 
Potassium, High 
(mEq/L; mmol/L) 5.6  to < 6.0 
5.6  to < 6.0 6.0  to < 6.5 
6.0  to < 6.5 6.5  to < 7.0 
6.5  to < 7.0 â‰¥ 7.0 
â‰¥ 7.0 
Potassium, Low 
(mEq/L; mmol/L) 3.0  to < 3.4 
3.0  to < 3.4 2.5  to < 3.0 
2.5  to < 3.0 2.0  to < 2.5 
2.0  to < 2.5 < 2.0 
< 2.0 
Sodium, High 
(mEq/L; mmol/L) 146  to < 150 
146  to < 150 150  to < 154 
150  to < 154 154  to < 160 
154  to < 160 â‰¥ 160 
â‰¥ 160 
Sodium, Low 
(mEq/L; mmol/L) 130  to < 135 
130  to < 135 125  to < 130 
125  to < 135 121  to < 125 
121  to < 125 â‰¤ 120 
â‰¤ 120 
Uric Acid, High 
(mg/dL; mmol/L) 7.5  to < 10.0 
0.45  to < 0.59 10.0  to < 12.0 
0.59  to < 0.71 12.0  to < 15.0 
0.71  to < 0.89 â‰¥ 15.0 
â‰¥ 0.89 
  
 
 
 
 
16 To convert a magnesium value from mg/dL to mm ol/L, laboratories should multiply by 0.4114.
Hematology  
    
PARA METER   
GRADE 1 
MILD  
GRADE 2 
MODERATE  
GRADE 3 
SEVERE  
GRADE 4 
POTENTIALLY 
LIFE- 
THREATENING 
Absolute CD 4+ Count, 
Low 
(cell/mm3; cells/L) 
 
> 5 years of age 
(not HIV infected)   
 
 
300 to < 400 
300 to < 400   
 
 
200 to <  300 
200 to < 300   
 
 
100 to < 200 
100  to < 200   
 
 
< 100 
< 100 
Absolute Lymphocyte 
Count, Low 
(cell/mm3; cells/L) 
 
> 5 years of age 
(not HIV infected)  
 
 
600  to < 650 
9 0.600 x 10   to 
< 0.650 x 109  
 
 
500  to < 600 
9 0.500 x 10   to 
< 0.600 x 109  
 
 
350 to < 500 
9 0.350 x 10   to 
< 0.500 x 109  
 
 
< 350           
9 < 0.350 x 10 
Absolute Neutrophil 
Count (ANC),  Low 
(cells/mm3; cells/L) 
 
> 7 days of age  
 
 
800 to 1,000 
0.800 x 109 to 1.000 
x 109  
 
 
600 to 799 
0.600 x 109 to 0.799 x 
109  
 
 
400 to 599 
0.400 x 109 to 0.599 x 
109  
 
 
< 400 
< 0.400 x 109 
2 to 7 days of age 1,250 to 1,500 
1.250 x 109 to 1.500 
x 109 1,000 to 1,249 
1.000 x 109 to 1.249 x 
109 750 to 999 
0.750 x 109 to 0.999 x 
109 < 750 
< 0.750 x 109 
â‰¤ 1 day of age 4,000 to 5,000 
4.000 x 109 to 
5.000 x 109 3,000 to 3,999 
3.000 x 109 to 3.999 x 
109 1,500 to 2,999 
1.500 x 109 to 2.999 x 
109 < 1,500 
< 1.500 x 109 
Fibrinogen, Decreased 
(mg/dL; g/L) 100  to < 200 
1.00 to < 2.00 
OR 
0.75 to < 1.00 
x LLN 75  to < 100 
0.75  to < 1.00 
OR 
â‰¥ 0.50 to < 0.75 
x LLN 50  to < 75 
0.50  to < 0.75 
OR 
0.25 to < 0.50 
x LLN < 50 
< 0.50 
OR 
< 0.25 x LLN  
OR Associated with 
gross bleeding 
Hemoglobin17, Low 
(g/dL; mmol/L)18 
 
â‰¥ 13 years of age 
(male only)   
 
10.0 to 10.9 
6.19 to 6.76   
 
9.0 to < 10.0 
5.57 to < 6.19   
 
7.0 to < 9.0 
4.34 to < 5.57   
 
< 7.0 
< 4.34 
â‰¥ 13 years of age 
(female only) 9.5 to 10.4 
5.88 to 6.48 8.5 to < 9.5 
5.25 to < 5.88 6.5 to < 8.5 
4.03 to < 5.25 < 6.5 
< 4.03 
 
 
 
 
17 Male and female sex are defined as sex at birth. 
18 The conversion factor used to convert g/dL to mm ol/L is 0.6206 and is the most commonly used conversion factor.  For grading hemoglobin 
results obtained by an analytic method with a conversion factor other than 0.6206, the result must be converted to g/dL using the appropriate 
conversion factor for the particular laboratory.
Hematology 
DAIDS AE Gradin g Table Version 2.0- Nov ember 2014 
Page 28  
    
PARA METER   
GRADE 1 
MILD  
GRADE 2 
MODERATE  
GRADE 3 
SEVERE  
GRADE 4 
POTENTIALLY 
LIFE- 
THREATENING 
57 days of age to < 13 
years of age 
(male and female) 9.5 to 10.4 
5.88 to 6.48 8.5 to < 9.5 
5.25 to < 5.88 6.5 to < 8.5 
4.03 to < 5.25 < 6.5 
< 4.03 
36 to 56 days of age 
(male and female) 8.5 to 9.6 
5.26 to 5.99 7.0 to < 8.5 
4.32 to < 5.26 6.0 to < 7.0 
3.72 to < 4.32 < 6.0 
< 3.72 
22 to 35 days of age 
(male and female) 9.5 to 11.0 
5.88 to 6.86 8.0 to < 9.5 
4.94 to < 5.88 6.7 to < 8.0 
4.15 to < 4.94 < 6.7 
< 4.15 
8 to â‰¤ 21 days of age 
(male and female) 11.0 to 13.0 
6.81 to 8.10 9.0 to < 11.0 
5.57 to < 6.81 8.0 to < 9.0 
4.96 to < 5.57 < 8.0 
< 4.96 
â‰¤ 7 days of age 
(male and female) 13.0 to 14.0 
8.05 to 8.72 10.0 to < 13.0 
6.19 to < 8.05 9.0 to < 10.0 
5.59 to < 6.19 < 9.0 
< 5.59 
INR,  High 
(not on anticoagulation 
therapy) 1.1  to < 1.5 x ULN 1.5  to < 2.0 x ULN 2.0  to < 3.0 x ULN â‰¥  3.0 x ULN 
Methemoglobin 
(% hemoglobin) 5.0  to < 10.0%  10.0  to < 15.0% 15.0  to < 20.0% â‰¥  20.0% 
PTT,  High 
(not on anticoagulation 
therapy) 1.1  to < 1.66 
x ULN 1.66 to < 2.33 
x ULN 2.33 to < 3.00 
x ULN â‰¥  3.00 x ULN 
Platelets, Decreased 
(cells/mm3; cells/L) 100,000  to 
< 124,999 
100.000 x 109  to 
< 124.999 x 109 50,000  to 
< 100,000 
50.000 x 109  to 
< 100.000 x 109 25,000  to 
< 50,000 
25.000 x 109  to 
< 50.000 x 109 < 25,000 
< 25.000 x 109 
PT, High 
(not on anticoagulation 
therapy 1.1  to < 1.25 
x ULN 1.25  to < 1.50 
x ULN 1.50  to < 3.00 
x ULN â‰¥  3.00 x ULN 
WBC, Decreased 
(cells/mm3; cells/L) 
 
> 7 days of age   
 
2,000 to 2,499 
2.000 x 109 to 2.499 
x 109   
 
1,500 to 1,999 
1.500 x 109 to 1.999 x 
109   
 
1,000 to 1,499 
1.000 x 109 to 1.499 x 
109   
 
< 1,000 
< 1.000 x 109 
â‰¤ 7 days of age 5,500 to 6,999 
5.500 x 109 to 6.999 
x 109 4,000 to 5,499 
4.000 x 109 to 5.499 x 
109 2,500 to 3,999 
2.500 x 109 to 3.999 x 
109 < 2,500 
< 2.500 x 109 
 
 
 
 
 
 
 
 
 
   
 Protocol Version 1.0  
     
     
PARA METER   
GRADE 1 
MILD  
GRADE 2 
MODERATE  
GRADE 3 
SEVERE  
GRADE 4 
POTENTIALLY 
LIFE- 
THREATENIN
G 
Glycosuria (random 
collection tested by 
dipstick) Trace to 1+ or 
â‰¤ 250 mg 2+ or Ëƒ 250 to 
â‰¤ 500 mg > 2+ or > 500 mg NA 
Hematuria (not to be 
reported based on dipstick 
findings or on blood 
believed to be of 
menstrual origin) 6  to < 10 RBCs  per 
high power field â‰¥ 10 RBCs  per high 
power field Gross, with or 
without clots OR 
With RBC  casts OR 
Intervention indicated Life-
threatening 
consequences 
Proteinuria (random 
collection tested by 
dipstick) 1+ 2+ 3+  or higher NA 
 
   
 Protocol Version 1.0  
     
                                   
 
APPENDIX F : ADVERSE EVENT REPORT ING FORM (FOR DSI)  
 
 
Daiichi Sankyo, Inc.  
Form Version 3.0, 08 Oct 2013  
 
 1 SERIOUS ADVERSE EVENT REPORT (SAVER) FORM  
 
Protocol 
#:       Site #:  
      Subject 
Initials:         
       
 
When completed, send to  <<CRO>> . 
Supplemental pages used (Mark all that apply) :  SAE   Lab Results   Concomitant Medications  
Report Type:   Initial   Follow -up #       
1. Source  
Investigator 
Name:        Country
:        
Address
:        
Phone 
#:       Fax #:  
       
     
2. Subject and Study Information  
Screening #/Subject 
#:       Randomization 
#:       Subject 
Initials:         
Birth Date: (dd Mmm 
yyyy)         Gender:   Male   Female  
Weight:   
kg  
lb        Height
:  cm  in        
Ethnicity
:  Hispanic or 
Latino   Not Hispanic or Latino  
Race:   Asian   Black   Caucasian   American Indian/Alaskan  Native  
  Native Hawaiian/Pacific 
Islander   Other         
Phase of Study at time of 
SAE:   Screening   Washout   Placebo/Run -in 
  Randomized   Post Study   Open -label  
Date of Informed Consent: (dd Mmm 
yyyy)         
   
3. Primary Serious Adverse Event  
(Use appropriate medical terminology, symptoms should be grouped together as syndromes and diagnosis.)  
If additional events are reported, use supplemental page.  If supplemental SAE pages were used, mark here:  
SAE 
(Event/Diagnosis):         
Date Event Became Serious: (dd Mmm 
yyyy)         Date Event Stopped ïƒ  or ïƒ : (dd Mmm 
yyyy)         
      
Continuing  Severity  Outcome  Seriousness Criteria  
(see protocol for SAE definitions)  
 Yes 
 No  Mild  
 Moderate  
 Severe   Recovered/Resolved  
 Recovered/Resolved with sequelae  
 Not Recovered/Not Resolved  
 Fatal  
 Unkno wn  Death  
 Life-threatening  
 Hospitalization -initial or prolonged  
 Disability or Permanent Damage  
 Congenital anomaly/Birth Defect  
 Important Medical Event  
 Not 
Applicable  Related  Not 
Related  
Study Procedure  (eg, Biopsy, CT scan, MRI scan, other protocol specified procedures; 
Separate from study drug administration)     
Daiichi Sankyo, Inc.  
Form Version 3.0, 08 Oct 2013  
 
 2 SERIOUS ADVERSE EVENT REPORT (SAVER) FORM  
 
Protocol 
#:       Site #:  
      Subject 
Initials:         
       
 
Is the event related to a study procedure?  
Study Drug Causality  (Complete one line for each study drug)  
Drug Name  Related  Not 
Related  
        
        
        
        
4. In Case of Death  
Date: (dd Mmm 
yyyy)         Autopsy:   Yes  No 
   Certificate
:  Yes  No 
Cause:         
         
5. Study Drug Dosing  
Record only dose given to subject at time of SAE .  Complete all previous dosing regimes including placebo 
run-in Section 6.  
Study Drug Dosing  Study Drug Action 
Taken  
Study Drug  Unit 
Dose  Frequency  Route  Start Date  
(dd Mmm yyyy)  Stop Date  
(dd Mmm yyyy)  
None  
Discontinued  
Reduced  
Interrupted  
Increased  
                                         
                                         
                                         
Was the subject withdrawn due to 
SAE?   Yes  No 
Was Study Drug Code broken due to 
SAE?   Yes  No If Yes, Date: (dd Mmm 
yyyy)         
Who:  
      Drug:  
      Dosing
:        
       
6. Previous Study Drug Dosing Regimens per Protocol, including placebo run -in. 
Study drug dosing at the time of SAEs is captured in Section 5.  Do NOT complete with â€œSee Attachedâ€.  
If not applicable mark here:  
Drug Name  Unit Dose  Frequency  Route  Start Date  
(dd Mmm yyyy)  Stop Date  
(dd Mmm yyyy)  
                                    
                                    
                                    
                                    
Daiichi Sankyo, Inc.  
Form Version 3.0, 08 Oct 2013  
 
 3 SERIOUS ADVERSE EVENT REPORT (SAVER) FORM  
 
Protocol 
#:       Site #:  
      Subject 
Initials:         
       
 
7. Relevant Concomitant Medications  
(Include those taken before the onset of the event, not taken as a treatment for the event.)  Do NOT complete with 
â€œSee Attachedâ€.   If Supplemental Concomitant Medication page is used, mark here:  
Generic/Brand 
Name  Dose  Frequency  Route  Start Date  
(dd Mmm 
yyyy)  Stop Date  
(dd Mmm yyyy)  Indication  Continuing
? 
                                           
                                           
                                           
                                           
                                           
                                           
8. Relevant Lab Results  
Do NOT complete with â€œSee Attached.â€   If supplemental Lab Results pages were used, mark here:  
Lab Test  Date  
(dd Mmm yyyy)  Results  Reference Normal 
Range (Units)  
                        
                        
                        
                        
                        
                        
9. Relevant Medical History Including Allergies  
Do NOT complete with â€œSee Attached.â€  
Date of Onset  
(dd Mmm yyyy)  Current  Past Description  (Mark one only)  
              
              
              
              
              
              
              
              
              
              
10. Narrative  
Record a detailed description of the event including the course of the event, evaluation, assessment and 
treatment . 
 
 
 
 
Daiichi Sankyo, Inc.  
Form Version 3.0, 08 Oct 2013  
 
 4 SERIOUS ADVERSE EVENT REPORT (SAVER) FORM  
 
Protocol 
#:       Site #:  
      Subject 
Initials:         
       
 
 
 
 
 
 
 
 
 
11. Person Completing This Form  
            
 Name   Signature   Date   
                 
 Title   Phone Number     
            
 Investigator Name   Signature   Date   
Daiichi Sankyo, Inc.  
Form Version 3.0, 08 Oct 2013  
 
Page 1 of 2 SERIOUS ADVERSE EVENT REPORT (SAVER) FORM  
(Supplemental SAE)  
 
Protocol #:        Site #:        Subject Initials:         
       
 
SAE (Event/Diagnosis) #: 2        
Date Event Became Serious: (dd Mmm yyyy)         Date Event Stopped ïƒ  or ïƒ : (dd Mmm yyyy)         
      
Continuing  Severity  Outcome  Seriousness Criteria  
(see protocol for SAE definitions)  
 Yes 
 No  Mild  
 Moderate  
 Severe   Recovered/Resolved  
 Recovered/Res olved with sequelae  
 Not Recovered/Not Resolved  
 Fatal  
 Unknown   Death  
 Life-threatening  
 Hospitalization -initial or prolonged  
 Disability or Permanent Damage  
 Congenital anomaly/Birth Defect  
 Important Medical E vent 
 Not 
Applicable  Related  Not Related  
Study Procedure  (eg, Biopsy, CT scan, MRI scan, other protocol specified procedures; Separate 
from study drug administration)  
Is the event related to a study procedure?     
Study Drug Causality  (Complete on e line for each study drug)  
Drug Name  Related  Not Related  
        
        
        
        
SAE (Event/Diagnosis) #: 3        
Date Event Became Serious: (dd Mmm yyyy)         Date Event Stopped ïƒ  or ïƒ : (dd Mmm yyyy)         
      
Continuing  Severity  Outcome  Seriousness Criteria  
(see protocol for SAE definitions)  
 Yes 
 No  Mild  
 Moderate  
 Severe   Recovered/Resolved  
 Recovered/Resolved with sequelae  
 Not Recovered/Not Resolved  
 Fatal  
 Unknown   Death  
 Life-threatening  
 Hospitalization -initial or prolonged  
 Disability or Permanent Damage  
 Congenital anomaly/Birth Defect  
 Important Medical Event  
 Not 
Applicable  Related  Not Related  
Study Procedure  (eg, Biopsy, CT scan, MRI scan, other protocol specified procedures; Separate 
from study drug administration)  
Is the event related to a study procedure?     
Study Drug Causality  (Complete one line for each study drug)  
Drug Name  Related  Not Related  
        
        
        
        
SAE (Event/Diagnosis) #: 4        
Date Event Became Serious: (dd Mmm yyyy)         Date Event Stopped ïƒ  or ïƒ : (dd Mmm yyyy)         
      
Continuing  Severity  Outcome  Seriousness Criteria  
(see protocol for SAE definitions)  
 Yes 
 No  Mild  
 Moderate  
 Severe   Recovered/Resolved  
 Recovered/Resolved with sequelae  
 Not Recovered/Not Resolved   Death  
 Life-threatening  
 Hospitalization -initial or prolonged  
Daiichi Sankyo, Inc.  
Form Version 3.0, 08 Oct 2013  
 
Page 2 of 2 SERIOUS ADVERSE EVENT REPORT (SAVER) FORM  
(Supplemental SAE)  
 
Protocol #:        Site #:        Subject Initials:         
       
 
 Fatal  
 Unknown   Disability or Permanent Damage  
 Congenital anomaly/Birth Defect  
 Important Medical Event  
 Not 
Applicable  Related  Not Related  
Study Procedure  (eg, Biopsy, CT scan, MRI scan, other protocol specified procedures; Separate 
from study drug administration)  
Is the event related to a study procedure?     
Study Drug Causality  (Complete on e line for each study drug)  
Drug Name  Related  Not Related  
        
        
        
        
Daiichi Sankyo, Inc.  
Form Version 3.0, 08 Oct 2013  
 
1 of 1  SERIOUS ADVERSE EVENT REPORT (SAVER) FORM  
(Supplemental Concomitant Medications)  
 
Protocol #:        Site #:        Subject Initials:         
       
 
7. Relevant Concomitant Medications (Continued)  
(Include those taken before the onset of the event, not taken as a treatment for the event.)  Do NOT complete with â€œSee 
Attachedâ€.  
Generic/Brand Name  Dose  Frequency  Route  Start Date  
(dd Mmm yyyy)  Stop Date  
(dd Mmm yyyy)  Indication  Continuing?  
                                           
                                           
                                           
                                           
                                           
                                           
                                           
                                           
                                           
                                           
                                           
                                           
                                           
                                           
                                           
                                           
                                           
                                           
                                           
                                           
Daiichi Sankyo, Inc.  
Form Version 3.0, 08 Oct 2013  
 
1 of 1  SERIOUS ADVERSE EVENT REPORT (SAVER) FORM  
(Supplemental Lab Results)  
 
Protocol 
#:       Site #:  
      Subject 
Initials:         
       
 
8. Relevant Lab Results (Continued)  
Do NOT complete with â€œSee Attached.â€  
Lab Test  Date  
(dd Mmm yyyy)  Results  Reference Normal 
Range (Units)  
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
Protocol version 2 .0 
 
 1  
APPENDIX G: SAMPLE INFORMED CONSENT FOR M (ICF)  
 
 
 
 
 
SUBJECT INFORMATION AND INFORMED CONSENT  FORM (ICF )  
 
Protocol : Targeted AntiCoagulation Therapy to Reduce Inflammation and 
Cellular Activation in Long-Term HIV Disease  
 
Short Title:  TACTICAL -HIV 
 
Funding : National Heart Lung and Blood Institute /National Institutes of  
Health  
Daiichi -Sankyo (study drug)  
 
Site: Hennepin County Medical Center (HCMC)  
 
Investigator :   Jason Baker, MD, MS  
 
  
CONSENT FOR PARTICIPATING IN AN N HLBI /NIH-FUNDED RESEARCH TRIAL  
 
 
INTRODUCTION AND PURPOSE: WHY IS THIS STUDY BEING DONE?  
You are invited to be in a research study that looks at the use of a medication that may 
improve the health of HIV positive people who are already on HIV medicines. The 
medication ( edoxaban ) is approved by the Food and Drug Administration (FDA), but not 
for treatment of HIV infection; it is commonly used to treat or prevent  blood clots .  
However, this medication may help address some of the damage that HIV causes in the 
body.  Forty HIV positive patients will be enrolled in this study  at HCMC in Minneapolis.   
 
Damage caused by HIV infection results in problems with the immun e system  and other 
organs in the body. One of these problems involves the coagulation system, which is how 
our bodies form blood clots to prevent bleeding.  HIV â€˜activatesâ€™ or turns on the 
coagulation system.  Over time this increases risk for having blood  clots and also results 
in â€˜inflammationâ€™ that can damage the body. Inflammation  occurs when the bodyâ€™s 
immune system is responding to injury or infection.  Inflammation can be helpful in the 
short term, but when it is persistent it can also cause more dam age to the body over time. 
These problems impair normal health over many years and cannot be fully corrected, 
even with  effective HIV treatment using  antiretroviral medications.   
 
Problems with clotting and o ngoing inflammation with damage to the body  contribute to 
risk for diseases like heart disease among HIV positive person s.  This study will determine 
if a low dose of edoxaban , which reduces blood clotting , will reduce inflammation .  If 
Protocol version 2 .0 
 
 2 successful, edoxaban may then be studied as an approach to achieve  normal health 
outcomes for persons with HIV infection.    
 
YOUR PARTICIPATION IS VOLUNTARY  
This consent form gives you information about the clinical research study that will be 
discussed with you.  Once you understand the study, and if you agree to take part, you 
will be asked to sign this consent form. You will be given a copy to keep.  
 
Before you learn about the study, it is important that you know the following:  
Your participation is entirely voluntary.  
 
You may decide not to take part or to withdraw  from the study at any time without losing 
the benefits of your routine medical care.  
 
Eligibility:  Who is being asked to be part of this research study?  
You may be  eligible for this study if you have HIV infection , you are taking your 
antiretroviral medi cations , you have evidence of increased coagulation (â€˜risk for clottingâ€™) 
based on a blood test, and you do not have contraindications to study procedures .  Your 
HIV â€˜viral loadâ€™ must be undetectable.  If your doctor or the study investigators feel that it  
would not be safe to take the study medication then you will not be eligible to participate. 
Some factors that could make you ineligible for this study include using other anti -clotting 
medications (â€˜blood thinnersâ€™) or having other inflammatory , liver or  kidney disease.  
 
HOW LONG WILL YOU BE  IN THE STUDY?  
The study will last approximately 12 months  and consists of 12 visits .  After the screening 
visit, if you qualify, you  will come in for a â€˜baselineâ€™ study visit, and then  follow -up visit s at 
1, 2, 3, 4, 7, 8, 9, 10, 11  and 12 months.  
 
HOW WILL THE STUDY W ORK?  
If you agree to participate in this study, you will be asked to take 30mg of edoxaban and 
a matching placebo pill once daily, but you would only be taking one medication at any 
given time during the study (i.e., you would not be taking edoxaban and placebo at the 
same time).  A t the beginning of the study  you will be randomly assigned to start one 
study medication, which will either be edoxaban or a matching placebo .  At month 4 you 
will stop taking s tudy medications.  At month 8 you will be asked to start the second study 
medication .  The second medication  will be placebo if your first medication was edoxaban, 
and will be edoxaban  if your first medication was placebo. Neither you, nor the study 
invest igators, will know which study medication you take first or second.   A picture of this 
process is then shown below.  
 
Protocol version 2 .0 
 
 3  
 
 
PROCEDURES:  WHAT DO  YOU HAVE TO DO IF YO U ARE IN THIS STUDY?  
 
Screening visit:  
You will be asked to come in for a screening visit, where your study investigators will 
review the study procedures and this consent form.  If you agree to participate, you will 
have your blood drawn (approximately 2 tablespoons) and medical history reviewed 
(similar to a  routine  clinic visit) to determine if you are eligible to participate.  If you meet 
study criteria, you will then return within 1 month  to begin the study.  
 
Baseline and follow -up (month 1,  2, 3, 4, 7, 8, 9, 10, 11,  12) clinic study visits:  
The baseline and follow -up clinical visit will las t approximately 1-2 hours, and will consist 
of: 
 
Medical History: You will be interviewed to review your medical history and assess your 
risk for developing heart disease.  We will also access your medical chart to obtain the 
results of recent lab tests an d medications you are taking.  
 
Blood Draw:  We will obtain a blood sample ( up to 8 tablespoons ) from a vein in your arm.  
The total blood draw volumes per visit will be less than 100 mL .  You must be fasting for 
at least 6 hours  prior to having your blood  drawn at study visits. Blood samples will be 
used to measure markers in the bl ood related to inflammation, coagulation (â€˜clottingâ€™) and 
other markers that may contribute to heart disease and other complications of HIV 
infection.  These samples may be stor ed for up to 20 years.  
 
At the baseline visit, you will start taking edoxaban  (or pla cebo). You will take 1 tablet (3 0 
mg) every da y in the morning . The nurses will give you the study medicine during your 
clinic visits. At follow -up visits you will be aske d to bring in all of your study medication, 
and adherence and tolerability to the treatment will be assessed.  
 
STORED SAMPLES  
During your participation in this study, blood will be collected by standard blood drawing 
techniques.  
 

Protocol version 2 .0 
 
 4 Samples will be used to evaluate the potential benefits of edoxaban. Additional samples 
will be store d up to 20 years for future research.  These samples can help us learn more 
about HIV, AIDS, immune function, inflammation, coagulation  (blood â€˜clottingâ€™ ), or other 
related diseases  that affect patients with HIV infection .  In general , the research tests we 
perform are not like routine medical tests and may not relate directly to your medical care.  
For this reason, we may not put future research test result s in your medical record or 
share these test results with your medical provider .  We will communicate any clinical labs 
obtained during the study to your primary medical provider.  
 
Genetic Testing  
Future research on stored samples might involve genetic tes ting.  Genetic testing may 
tell researchers something about how health or illness is passed on to you by your parents 
or from you to your children.  Some genetic information, such as the ability to make certain 
proteins in the body, has been associated with  an increased risk of certain diseases like 
arthritis.  
 
Any genetic information collected or discovered about you or your family will be 
confidential. Genetic information about you will not be revealed to others, including your 
relatives, without your per mission.  We will not release any information about you or your 
family to any insurance company or employer unless you sign a document allowing 
release of information.  
 
HOW WILL YOU GET MEDICINES FOR THE STUDY?  
Study medications will be provided to you by the study and will be distributed by study 
nurses during study visits.   You will be provided with sufficient supply to last the duration 
of the study.  You will be asked to return any unused study medication, including empty 
containers.  
 
WHAT ARE THE RISK S AND/OR DISCOMFORTS OF THIS STUDY?  
 
You will be monitored for side effects at each visit, and your lab tests will include an 
evaluation for signs of medication toxicity.  
 
Risks of Study Procedures  
You will have your blood drawn at each study visit. This is identical to having your blood 
drawn at a medical clinic, and can involve discomfort, light -headedness and/or minor 
bruising . Discussion of past medical history or risk factors for HIV infection may be 
stressful and cause anxiety. You may decline to ans wer any questions that you do not 
feel comfortable answering.  
 
Study Medication: Edoxaban  
This medication is approved by the FDA. Edoxaban is used to prevent and treat blood 
clots. The most significant possible side effects of edoxaban is bleeding.  This m ay be 
mild, like a bloody nose, or more significant and require medical evaluation.  Examples 
of serious or major bleeding from edoxaban include bleeding in the stomach or 
intestines, or bleeding in the brain.  Major bleeding events were rare, occurring be tween 
1-2% of the time, in prior clinical studies of edoxaban.  We will ask you about signs or 
symptoms of bleeding during each of your visits, such as abdominal pain, black stools, 
dizziness, lightheadedness, fatigue, or headache.  We will also monitor yo ur blood 
Protocol version 2 .0 
 
 5 results for signs of bleeding at each visit.  We do not expect that edoxaban will interact 
with any of your HIV medicines.   
 
This medication should not be used during pregnancy. If a developing fetus is exposed 
to edoxaban, injury or even death m ay result. For this reason, if you are a woman of 
childbearing potential, you  will be asked what type of birth control you use. You must be 
willing to use a reliable form of birth control for the duration of the study period, such as 
a barrier method or sp ermicide. Condoms cannot be the only form of birth control you 
use. If you become pregnant during the study or think you may be pregnant, you should 
inform either the site investigator or a study nurse immediately. We will ask that you return 
any study med ication. We will ask permission to contact you at the end of the pregnancy 
to check on the health of you and the baby.  
 
WHAT ABOUT PREGNANCY AND BREASTFEEDING?  
If you are pregnant, breastfeeding or planning to become pregnant, you will not be eligible 
for this study.  If you become pregnant during the study, you will be asked to stop study 
medications and withdraw.  Therefore, if it is possible that you could become pregnant, 
we ask that you use a reliable form of birth control  for the duration of the study  (listed 
above in â€˜Study Medicationâ€™).  
 
WHAT ARE THE BENEFITS OF THIS STUDY?  
If you take part in this study, there are no anticipated benefits directly to your health.  The 
research has the potential to benefit people with HIV infection, after the study is completed 
and the findings have been  analyzed.   
  
COMPENSATION  
You will be paid $ 25 for each study visit you attend after the screening visit.  You may 
receive a total of $275 for participating in the study.  Study investigators may ask for your 
social security number as part of the monitoring process for this compensation.  
 
WHAT IF THERE ARE NEW FINDINGS?  
We will not be analyzing data during the study.   However, if during the course of this 
research study, there are significant new findings discovered which might influence your 
willingness to continue, the researchers will inform you of those developments.  You may 
request your own results after the stu dy by contacting the research investigators.  
 
WHAT IF YOU DONâ€™T WANT TO BE IN THE STUDY ANY LONGER?  
If you enroll in this study, you may decide to stop participating at any time.  Withdrawing 
from this study will not affect the benefits of your regular medical care.   
 
CAN YOUR STUDY PARTICIPATION BE STOPPED WITHOUT YOUR CONSENT?  
You may be taken off of  study medicines before the end of the study if investigators or 
your doctor recommend this.  You may be taken off the entire study without your consent 
if: 
ï‚· Your study doctor decides that continuing in the study would harm you;  
ï‚· Your lab results indicate th at you are experiencing toxicity from study medications;  
 
WHAT OTHER CHOICES DO YOU HAVE BESIDES THIS STUDY?  
You may discuss other strategies for improving your health with your doctor.  
Protocol version 2 .0 
 
 6  
WHAT ARE THE COSTS TO YOU?  
The medications that are part of this st udy will be provided free -of-cost to you, and will be 
distributed during study visits.    During the study, you, your insurance company, or some 
other third -party payer must pay for all other medicines, including HIV medicines not paid 
by the study and medi cines needed to prevent or treat other illnesses.  We will provide all 
clinical and professional services, lab work, and other tests that are part of this study and 
not part of your regular care at no cost to you.  
 
HOW IS YOUR PRIVACY PROTECTED?  
Any infor mation that could be used to identify you will be treated in strict confidence to 
the extent allowed by law.  Nevertheless, some uses and disclosures of your information 
are necessary to conduct the study.  If you agree to be part of this study, you will a lso be 
allowing the uses and disclosures of your private health information as needed for the 
purposes of this study as described in this consent.  
 
â€œPrivate health informationâ€ means information that identifies you and is collected:  
ï‚· during this study;  
ï‚· from your past and current medical records maintained by your regular health care 
providers, to the extent the information is relevant to this study or to your eligibility for 
this study; or  
ï‚· from any payment records relating to items or services furnished to you during this 
study.  
 
By signing this consent, you are agreeing that your private health information may be 
disclosed to and used by:  
ï‚· the doctors and other health care providers involved in this study;  
ï‚· their staff;  
ï‚· the research center;  
ï‚· members of this institutionâ€™s Human Subjects Research Committee/Institutional 
Review Board;  
ï‚· Daiichi -Sankyo ; 
ï‚· the sponsor of this study and its agents; and  
ï‚· monitors from the United States Government and/or Food and Drug Administration 
(FDA).  
 
The findings of this study may be used for scientific meetings, written reports, and 
publications, but no information that could be used to identify you will be disclosed for 
these purposes.  
 
Once your private health information has been disclosed to a third party, federal privacy 
laws may no longer protect it from re -disclosure.  However, anyone obtaining access to 
your private health information under this consent must agree to protect your information 
as required by this consent.   
 
This consent to use your private health information as described above does not expire. 
However, if you later change your mind, you can revoke this consent by writing to Dr. 
Jason Baker  [701 Park Avenue; Mail Code G5; Minneapolis, MN 55415; phone 612 -873-
Protocol version 2 .0 
 
 7 2705]  saying that you  no longer wish to allow your pr ivate health information to be used 
for this study.  If you revoke your consent, you may no longer be able to participate in the 
study.  Moreover, we cannot undo uses or disclosures of your private health information 
that have already taken place in relian ce on your prior consent.  
 
PLEASE NOTE:  
A) In the event of a positive result for Hepatitis B or C, we may be required to 
report these  results to the local state Depa rtment of Health . 
 
B) Lab results from this study that are also part of clinical care may b e entered into 
the electronic medical record (EPIC) at Hennepin County Medical Center.  These 
lab results may then be viewed by your medical provider(s) and other allied health 
professionals.  
 
WHAT IF YOU ARE INJURED?  
 
If you are injured as a result of be ing in this study, you will be given immediate treatment.  
The cost for treatment will be charged to you or your insurance company.  There is no 
program through this institution to compensate participants who have research related 
injuries. You will not be  giving up any of your legal rights by signing this consent.  
 
WHAT IF YOU HAVE PROBLEMS OR QUESTIONS?  
If you ever have questions or in the case of research -related injuries, you should contact:  
 
Hennepin County Medical Center  
Minneapolis, Minnesota, Unit ed States 55417  
Principal Investigator: Jason Baker, MD, MS    
Phone: 612-873-2700  Email: baker@umn.edu  
 
Contact: Andrea Dolan, BS  
Phone:  612-873-7678  Email: andrea.nolan@hcmed.org  
 
If you have questions about research  subjectâ€™s rights you can contact : 
 
Human Subjects Research Committee  
Hennepin County Medical Center  
Contact: Karen Heim -Duthoy  
Phone: 612 -873-6882   Email: heimd001@umn.edu  
 
RESEARCH STUDY REGISTRY  
A description of this clinical trial will be available on http://www.ClinicalTrials.gov , as 
required by U.S. Law.  This Website will not include information that can identify you.  At 
most, the Website will include a summary of the results.  You can search this Websit e at 
anytime.  
Protocol version 2 .0 
 
 8 SIGNATURE PAGE FOR CONSENT TO PARTI CIPATE IN  THE TACTICAL -HIV 
STUDY  
 
As part of our ongoing research studies to better understand disease and improve health 
we often contact patients about clinical studies for which they may be eligible to 
participant.  By signing this consent, you would also authorize us to contact you abo ut 
future studies.  If you would prefer we not contact you directly about future studies, please 
indicate this by placing a check after 'do not contact me' and then initialing.  
 
Do not contact me for future studies: _________   Initial: __________  
 
 
I hav e read this consent form, had the opportunity to ask questions and have received 
answers to any questions I have asked.  I willingly give my consent to participate in this 
study, and authorize the use and disclosure of my health information as described in  this 
form.  By signing this consent form I do not give up any of my legal rights.  Upon signing 
this form I will be given a signed copy of the form for my records.  
 
If you have read the consent (or if you have had it explained to you) and understand the 
information, and you voluntarily agree to join this study, please sign your name below.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
______________________  ______________________  ___________  
Participantâ€™s name    Participantâ€™s signature    Date  
(typed or printed)  
 
 
 
_________________________________    _______________  
  
Person obtaining consent       Date  
 
 
 
 